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ABSTRACT: Chemotherapy with platinum complexes is essential
for clinical anticancer therapy. However, due to side effects and
drug resistance, further drug improvement is urgently needed.
Herein, we report on triple-action platinum(IV) prodrugs, which,
in addition to tumor targeting via maleimide-mediated albumin
binding, release the immunomodulatory ligand 1-methyl-D-
tryptophan (1-MDT). Unexpectedly, structure−activity relation-
ship analysis showed that the mode of 1-MDT conjugation
distinctly impacts the reducibility and thus activation of the
prodrugs. This in turn affected ligand release, pharmacokinetic
properties, efficiency of immunomodulation, and the anticancer
activity in vitro and in a mouse model in vivo. Moreover, we could
demonstrate that the design of albumin-targeted multi-modal prodrugs using platinum(IV) is a promising strategy to enhance the
cellular uptake of bioactive ligands with low cell permeability (1-MDT) and to improve their selective delivery into the malignant
tissue. This will allow tumor-specific anticancer therapy supported by a favorably tuned immune microenvironment.
■ INTRODUCTION
The antitumor activity of cisplatin was already discovered in
the 1960s, resulting in its approval in 1978.1,2 Subsequently,
two additional platinum(II) complexes, carboplatin and
oxaliplatin, have been approved worldwide.3 This compound
class is still widely used as a first-line treatment in many
therapeutic schemes and has more recently caused another
surge of interest, due to its synergism with immune checkpoint
inhibitors like pembrolizumab.3 Moreover, it is already widely
accepted that oxaliplatin requires an intact immune system to
fully unfold its anticancer activity.3 However, the low
selectivity of platinum drugs for the malignant tissue is still a
major limitation as treatment with these compounds frequently
results in severe side effects.4 Additionally, intrinsic or acquired
resistance, often based on reduced drug accumulation in the
cancer tissue, represents another major drawback.5 Con-
sequently, drug combination strategies, exploiting the specific
cancer biology, are of high interest to improve the efficacy of
therapy in tandem with reduced side effects.
Cancer cells are known to actively inhibit immune
recognition through diverse mechanisms, including loss of
the antigen-presenting machinery or expression of inhibitory
molecules and enzymes that induce T-cell suppression.6 One
specific enzyme is indoleamine 2,3-dioxygenase (IDO), which
catabolizes the amino acid tryptophan (Trp) to kynurenine
(Kyn). Binding of Kyn to the aryl hydrocarbon receptor
inhibits T-cell activation and supports regulatory T-cell
proliferation.7 IDO expression has been described for several
tumor types and identified as a major mechanism supporting
immune evasion of cancer cells. The interest in this enzyme is
also reflected by the clinical development of several IDO
inhibitors, such as 1-methyltryptophan (1-MT).8 In numerous
preclinical studies, 1-MT has been investigated, both as pure
stereoisomers as well as racemic mixtures.9−11 Interestingly,
even though the L-isomer [1-methyl-L-tryptophan (1-MLT)]
inhibits IDO more efficiently in cell culture, the D-isomer [1-
methyl-D-tryptophan (1-MDT); indoximod] has emerged as
preferential compound for clinical development, due to its
higher immunogenic anticancer activity in vivo.10 With regard
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Scheme 1. (A) Synthetic Routes for 1-MDT and Maleimide Building Blocks; (a) 60% HClO4, t-Butyl Acetate, 0 °C−Room
Temperature (RT); (b) 1,1′-Carbonyldiimidazole, N,N-Diisopropylethylamine (DIPEA), Dichloromethane (DCM), RT; (c)
Dimethyl Sulfoxide (DMSO), 80 °C; (d) Di-t-butyl Dicarbonate, NaOH, Dioxane/Water 2:1, RT; (e) Diphenylphosphoryl
Azide (DPPA), Triethylamine (TEA), Toluene; and (f) Toluene, 100 °C; (B) Synthetic Routes for the Final Maleimide−
Platinum(IV) 1-MDT Complexes; (g) H2O2 (50% w/w), H2O, RT; (h) 6a, DMSO, RT; (i) 4, TBTU, TEA,
Dimethylformamide (DMF), RT; (j) 10% TFA in DCM, RT; (k) 3, DMSO, RT; (l) 6a, DMF, RT; (m) 5, N-Ethyl Maleimide,
TBTU, TEA, DMF, RT; and (n) 4, 6a, TBTU, TEA, DMF, RT
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to platinum drugs, there is strong evidence that the
combination with IDO inhibition (e.g., by 1-MDT) is highly
synergistic.12−15 There are already some promising reports on
nano-formulations combining platinum-based chemotherapy
with IDO inhibitors.13,14,16 However, such nano-formulations
exhibit various major limitations for clinical use including
challenging preparation procedures, difficulties in batch-to-
batch reproducibility, stability/shelf-life, and varying loading
efficiency.17 Therefore, other more stable and controllable
approaches are of interest, such as platinum(IV) prodrugs.
Platinum(IV) complexes are promising tools to design multi-
modulatory drugs as they are not only kinetically more inert
than their platinum(II) counterparts but also offer the ability
to attach additional ligands.18,19 Thus, upon reduction,
platinum(IV) complexes release both, the cytotoxic
platinum(II) species and the bioactive compound(s). In this
way, simultaneous, tumor-specific release of two or more drugs
is possible, which can target the cancer cells by different and
ideally synergistic modes of actions.20 Moreover, this strategy
is especially interesting for ligands which are characterized by a
low cell penetration. The clinically investigated IDO inhibitor
1-MDT is a zwitterionic amino acid under physiological pH
conditions, which hampers its cellular uptake. Consequently,
usually very high levels of 1-MDT have to be applied for
sufficient activity. Formation of a platinum(IV) prodrug with
intracellular release of 1-MDT is an elegant way to modulate
the characteristics of this IDO inhibitor. Recently, the first
prodrug approach using cisplatin-releasing complexes and an
albumin-targeting prodrug strategy has been reported by
Awuah et al.16
Binding to serum albumin represents one of the most
efficient strategies to target the tumor tissue.21,22 Due to the
fact that albumin serves as a transporter for several nutrients in
the blood stream, fast-growing tumor cells are characterized by
an increased uptake of this plasma protein and additionally use
albumin as an amino acid source.23 Furthermore, the enhanced
permeability and retention effect, that is based on the
combination of leaky blood vessels together with impaired
lymph drainage, contributes to albumin accumulation in the
malignant tissue.24,25 The potential of targeting cancer cells by
their enhanced need for albumin has been demonstrated by
nab (nanoparticle albumin-bound) paclitaxel (ABRAXANE),
which is already approved for treatment of various cancer
types.26,27 In addition, aldoxorubicin, a compound which
successfully finished a phase III clinical trial (study number
NCT02049905) in soft tissue sarcoma, is of note. This
compound utilizes a maleimide moiety, which specifically
targets the single free cysteine residue of albumin at position
34.28 We have recently reported on the first maleimide-bearing
platinum(IV) complexes.29,30 Here, especially, the oxaliplatin
derivatives not only showed excellent reduction properties and
tumor accumulation but also promising antitumor activity in
vivo.29 Noteworthy, our studies revealed that for the success of
an albumin-targeted prodrug strategy, very stable platinum(IV)
complexes are necessary. Platinum(IV) complexes with a
cisplatin core faced much faster reduction kinetics (compared
to oxaliplatin or carboplatin derivatives)31,32 and are therefore
less ideal for long-circulating drug delivery systems like
albumin-conjugated prodrugs.29 Indeed, in the study by
Awuah et al., the IDO-releasing cisplatin drug faced several
problems. The authors used a very lipophilic C16−alkyl chain
for non-covalent albumin binding and, consequently, the
compound was hardly soluble and had to be encapsulated into
polylactide-co-glycolide−polyethylene glycol polymers to
achieve sufficient solubility. Despite their efforts, the in vivo
plasma half-life of the drug was only 1 h, indicating that the
effect of the albumin nano-carrier did not apply. In order to
successfully develop tumor-specific 1-MDT-releasing prodrugs,
new complexes with enhanced stability and albumin-binding
properties are required to achieve high tumor accumulation
and anticancer activity. Based on their high reduction stability,
oxaliplatin-releasing compounds are ideal candidates for this
approach. Moreover, oxaliplatin is known for its strong
immunogenic activity and promising synergistic activity with
IDO inhibitors.13,33,34
In the present study, we designed the first oxaliplatin-based
albumin-targeted platinum(IV) complexes with an 1-MDT
ligand. For endogenous albumin targeting, ideally maleimides
are used because of their exceptionally fast binding rates in
serum and sufficient solubility for in vivo studies. Other
moieties usually suffer either from very low solubility (long
aliphatic alkyl chains16) or too slow binding kinetics (e.g.,
carbonylacrylic reagents35). In order to generate a lead
candidate for further preclinical investigations, several 1-
MDT-bearing derivatives with different maleimide linkage
types were synthesized to investigate chemical and pharmaco-
logical drug properties. As maleimide compounds are difficult
to test in cell culture due to their proneness to hydrolysis and
their reactivity with cell medium components, succinimide
derivatives were additionally synthesized for in vitro analysis.
■ RESULTS AND DISCUSSION
Synthesis. It is known that the exact ligand coordination
and inner sphere of a platinum(IV) core are substantial for its
reduction behavior.36,37 Therefore, we decided to elucidate the
detailed structure−activity relationships for the platinum(IV)
prodrugs by synthesizing four distinctly different complexes
based on the axial ligand-binding motifs of the maleimide and
IDO inhibitor. 1-MDT is an amino acid that possesses two
functional groups, which are potentially suitable for coupling to
the platinum core: the carboxylic acid to form a carboxylate (in
this manuscript denoted as “ester”) and the primary amine
with formation of a carbamate. Notably, so far only the
“straightforward” coupling via the carboxylic acid has been
reported.16 We successfully established the ester coupling to
the oxaliplatin core using 2-(1H-benzotriazole-1-yl)-1,1,3,3-
tetramethylaminium tetrafluoroborate (TBTU) and the
carbamate formation via isocyanates (Scheme 1). To obtain
the building blocks for further synthesis, on the one hand, the
carboxylic acid moiety of 1-MDT was protected via t-butyl
ester (1) before converting the amine to isocyanate (3) using
1,1′-carbonyldiimidazole (Scheme 1A). On the other hand,
Boc-protection of the primary amine resulted in the ester-
building block 4. Maleimide moieties were similarly coupled
either as a commercially available carboxylic acid (5a) or as an
isocyanate (6a) (Scheme 1A). The oxaliplatin precursors were
obtained by oxidation with H2O2 in water yielding the
dihydroxido complex (7a) or in acetic acid with formation of
the mono-acetato complex (7b).38,39 Subsequent reactions of
7a with either isocyanate building block yielded intermediates
8a or 9 (Scheme 1B). To generate the final complex MalCa/
IdoCa [maleimide via carbamate, 1-MDT as an IDO inhibitor
(Ido) via carbamate], complex 9 reacted further with
maleimido-isocyanate 6a. For MalEs/IdoCa [maleimide via
ester, 1-MDT as an IDO inhibitor (Ido) via carbamate] and
MalCa/IdoEs [maleimide via carbamate, 1-MDT as an IDO
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inhibitor (Ido) via ester], the respective carbamato-inter-
mediate 8a or 9 reacted with the other respective carboxylic
acids via TBTU-mediated coupling (in case of 8a, N-ethyl
maleimide was added to the reaction mixture in order to
prevent adduct formation of the TBTU side product with the
maleimide of 8a). With regard toMalEs/IdoEs [maleimide via
ester, 1-MDT as an IDO inhibitor (Ido) via ester], the
coupling of both ligands was performed using a one-pot
procedure. In all cases, subsequent deprotection with trifluoro-
acetic acid (TFA) yielded the final products after preparative
high-performance liquid chromatography (HPLC) purification.
In parallel, the respective succinimides of all four complexes
(SucCa/IdoCa, SucCa/IdoEs, SucEs/IdoCa, and SucEs/
IdoEs, Figure 1) were synthesized in an identical manner
using the succinimide precursors (5b and 6b). In addition, the
acetato-derivative SucCa/OAc was prepared from the
hydroxido/acetato platinum(IV) precursor 7b using isocyanate
6b (see the experimental section part).
Albumin Binding and Serum Stability. As a first step,
we investigated the albumin-binding kinetics and serum
stability of the novel maleimide-bearing drugs by size exclusion
chromatography followed by inductively coupled plasma mass
Figure 1. Structures of platinum(IV) reference compounds for cell culture investigations.
Figure 2. Platinum-SEC−ICP−MS traces of the complexes (A) MalEs/IdoCa, (B) MalCa/IdoCa, (C) MalCa/IdoEs, and (D) MalEs/IdoEs
after incubation in FCS at 37 °C after 0, 1, and 24 h. The small peaks at ∼11 min retention time indicate the initial low-molecular-weight
complexes; the peaks at ∼4 min indicate the albumin-bound platinum.
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spectrometry (SEC−ICP−MS) after incubation in fetal calf
serum (FCS, buffered with 150 mM phosphate buffer to
ensure a stable pH over 24 h and 1% DMF for sufficient
solubility) at 37 °C (Figure 2). Already at t = 0, most of the
platinum was bound to the albumin fraction with a retention
time of ∼4 min, and only small amounts were present in the
low-molecular-weight region at around 10−12 min (a
chromatogram of the sulfur trace of pure serum can be
found in Figure S1). After 1 h, no low-molecular-weight
platinum species could be detected in either of the samples
(Figure 2). This confirms very fast albumin-binding properties
of all four derivatives. Interestingly, derivatives with 1-MDT
coupled via an ester to the platinum(IV) core conjugated
slightly faster to albumin than the derivatives with an 1-MDT
carbamate bond to the metal. Moreover, the results also
suggest that Michael addition to the thiol proceeds
substantially quicker than hydrolysis of the maleimide, which
would generate a species in the low-molecular-weight region
unable to bind to albumin. The data also clearly indicate high
stability of all complexes in serum without significant
degradation of the platinum(IV) albumin adduct within 24
h. As reference measurements, also the succinimide analogues
were investigated by SEC−ICP−MS in serum (Figure S2). No
significant binding to albumin or other proteins could be
observed, proving that the maleimide is indeed the crucial
moiety for coupling.
Reduction Properties. As already mentioned, one of the
most crucial parameters in the biological activity of platinum-
(IV) drugs is their ability to be reduced in tumor tissue.
Recently, we have demonstrated that in case of maleimide-
bearing complexes,29 slow-reducing platinum(IV) derivatives
are characterized by a longer plasma half-life time, improved
tumor accumulation, and superior anticancer activity in vivo.
However, the compounds should not be too stable as the
platinum(IV) prodrugs need to be activated via reduction in
the specific microenvironment of the tumor in order to exert
their antitumor potential.36 Due to the hydrolysis of the
maleimide moiety, we analyzed the reduction properties of the
respective succinimide complexes by ultra-HPLC (UHPLC)
after incubation in phosphate buffer at pH 7.4 (including 1%
DMF) with a 10-fold excess of L-ascorbic acid (AA) as a
reducing agent. Notably, huge differences between the
platinum complexes could be observed. Unexpectedly, both
complexes with ester-like 1-MDT conjugations (SucEs/IdoEs
and SucCa/IdoEs) were completely reduced within 2 h
(Figure 3). In comparison, the carbamate analogues SucEs/
IdoCa and SucCa/IdoCa displayed the expected very high
stability in the reductive environment with 90% of the complex
being intact after 6 h (Figure 3). This slow reduction behavior
is in line with several literature reports on other oxaliplatin(IV)
complexes.29,40−42 In contrast, the binding mode of the
maleimide moiety did not substantially influence the reduction
properties of these complexes. However, the question
remained how this dramatic divergence in the reduction
kinetics, just by changing the coordination mode of 1-MDT
from an ester to a carbamate, can be explained. The main
difference is that in case of SucEs/IdoEs and SucCa/IdoEs
the amino group of 1-MDT is free, whereas in case of SucEs/
IdoCa and SucCa/IdoCa, a free carboxylic acid is present.
Therefore, it can be concluded that the very fast reduction is
associated with the free amino group of the ester-bound
complexes. To investigate this hypothesis, an analogue using 1-
methyl-indole-3-propanoic acid lacking the amino group was
synthesized (OAc/IPAEs; Figure 1). Subsequently, incubation
studies with AA indeed revealed comparable reduction kinetics
to the carbamate-linked complexes (Figure S3A). Therefore, it
can be assumed that the electron transfer is facilitated by an
interaction/stabilization of the reducing agent with the amine.
This phenomenon is not specific for AA but was also visible
when using DL-dithiothreitol as a reductant. Again, distinctly
slower reduction kinetics were observed for OAc/IPAEs in
comparison to SucCa/IdoEs (Figure S4).
Impact of the Different Reduction Kinetics on the
Anticancer Activity of the Succinimide Prodrugs. To
evaluate whether the observed differences in the reduction
kinetics also influence the biological activities of the
compounds, the cytotoxicity of the new drugs was determined
in cell culture after 48 and 72 h. Since oxaliplatin is clinically
used against gastrointestinal cancers, two colon carcinoma cell
lines, one of human (HCT116) and one of murine origin
(CT26), were analyzed for this purpose (Table 1 and Table
S1). In general, we observed a similar structure activity pattern
in both models. In more detail, all platinum(IV) drugs
exhibited higher IC50 values than free oxaliplatin. This was
not unexpected as based on the prodrug nature of these
Figure 3. Reduction kinetics measured by UHPLC of succinimide
complexes (1 mM) at 20 °C with a 10-fold excess of AA in phosphate
buffer (500 mM, pH 7.4) containing 1% DMF.
Table 1. Cytotoxicity Determined by MTT Assay in Murine
CT26 and Human HCT116 Colon Cancer Cells after 48 h
Incubation with and without 5 equiv AAa
+AA
mean ± SD mean ± SD ratio
CT26IC50 Values (μM)48 h
oxaliplatin 1.50 ± 0.39 1.53 ± 0.25 0.98
OAc/OAc 25.66 ± 1.40 22.60 ± 0.16 1.14
SucCa/OAc 75.21 ± 0.11 28.17 ± 1.81 2.67
SucEs/IdoCa >100 26.65 ± 0.75 ≥3
SucCa/IdoCa >100 38.84 ± 3.84 ≥2.6
SucEs/IdoEs 91.51 ± 3.84 11.15 ± 0.37 8.21
SucCa/IdoEs 60.09 ± 6.49 10.81 ± 1.04 5.56
HCT116IC50 Values (μM)48 h
oxaliplatin 0.72 ± 0.01 0.67 ± 0.01 1.07
OAc/OAc 26.56 ± 2.41 20.10 ± 1.57 1.32
SucCa/OAc >100 33.96 ± 1.58 ≥2.9
SucEs/IdoCa >100 35.39 ± 6.54 ≥2.8
SucCa/IdoCa >100 43.27 ± 2.10 ≥2.3
SucEs/IdoEs 22.80 ± 1.15 6.94 ± 0.33 3.28
SucCa/IdoEs 26.00 ± 3.21 7.36 ± 1.14 3.53
aValues are given as mean ± standard deviation (SD).
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compounds, they need additional time to be activated and to
release their active platinum(II) species. Accordingly, the
derivatives with ester-like 1-MDT conjugations (SucEs/IdoEs
and SucCa/IdoEs), which were characterized by faster
reduction, were more active than the 1-MDT carbamate-
linked analogues (SucEs/IdoCa and SucCa/IdoCa) with
higher reduction stability. In detail, after 48 h, the 1-MDT
carbamate-linked complexes did not show any anticancer
activity up to the highest concentration of 100 μM in both cell
lines. In contrast, the 1-MDT ester-linked complexes had IC50
values of ∼60−90 μM in CT26 cells and ∼25 μM in HCT-116
cells after 48 h. The same trends were also visible after 72 h,
although all compounds were more active than after 48 h
(Table S1). The coordination of the succinimide moiety via
ester or a carbamate only minimally influenced the
antiproliferative activity. There was also a distinct difference
between the two platinum(IV) reference drugs, with OAc/
OAc being at least 3-fold more active than SucCa/OAc.
Noteworthy, the ratio between the activity of oxaliplatin and
the platinum(IV) complexes became distinctly smaller upon
longer incubation times (e.g., in case of SucEs/IdoEs in CT26
cells from a factor of 61 to a factor of 24). This again indicates
that prolonged incubation provides sufficient time for more
complete reduction and, thus, oxaliplatin release. To further
investigate this hypothesis, the activity of the compounds was
tested in the presence of 5-fold excess AA as an reducing agent
(Figure S5). While the addition of AA did not have any effect
on the cytotoxic properties of oxaliplatin, the anticancer
activity of our new compounds was considerably enhanced
after 48 h. This effect was reduced, when we increased the
incubation time of the cytotoxicity assays from 48 to 72 h.
Here, especially in case of HCT116 cells (Table S1), addition
of AA had basically no additional effect on the two fast
reducing compounds, indicating that in this time frame, full
reduction of the platinum(IV) was already achieved without
additional AA. With regard to the reference drugs, SucCa/
OAc, lacking the free amino group, behaved as anticipated,
similar to the carbamate-linked complexes. In contrast, OAc/
OAc could not be further activated by addition of AA. This is
unexpected as the reduction kinetics of these two compounds
were comparable (Figure S3B). To evaluate whether reduction
leads to the release of a functional platinum(II) species from
our prodrugs, we investigated the induction of two main
hallmarks of oxaliplatin activity upon addition of AA: DNA
damage indicated by phosphorylation of histone H2A.X at
position Ser139 and cell cycle arrest in G2/M due to activation
of the DNA damage sensor P53.43 As shown in Figures S6 and
S7, reduction by AA resulted in both, increased pH2A.X
signals and an increased fraction of cells in the G2/M phase of
the cell cycle similar to oxaliplatin, especially in case of the fast
reducing agents SucEs/IdoEs and SucCa/IdoEs.
Finally, the effects of our prodrugs on healthy tissue were
tested in non-malignant cell lines (Table S2). As kidney and
liver tissue are typically strongly affected by therapy with
platinum compounds, we chose human embryonic kidney cells
(HEK293) and human hepatic (WRL68) cells for these
experiments. The experiments revealed that while both cell
lines were very sensitive to oxaliplatin treatment in the low μM
range, the prodrugs were up to 40-fold less toxic, suggesting a
low side-effect profile of our compounds.
In order to rule out that the observed effects in the viability
assays were based on differences in the uptake between fast-
and slow-reducing prodrugs, we investigated the intracellular
platinum levels after 3 h incubation in HCT116 cells. Several
interesting observations were made (Figure 4): (1) The
platinum(II) complex, oxaliplatin, was taken up by the cells
much more efficiently than any of the platinum(IV) prodrugs.
(2) Compounds that carry a 1-MDT ligand are taken up at
higher levels than the platinum(IV) reference compounds
OAc/OAc and SucCa/OAc. (3) There was no significant
difference in the platinum levels of cells treated with different
1-MDT-bearing complexes. Lipophilicity is a parameter known
to impact on the cellular drug accumulation and, thus,
cytotoxicity. Hence, compounds with higher lipophilicity
usually have higher cellular uptake and cytotoxicity. In order
to assess this criterion, we determined the log D7.4 value for
oxaliplatin, OAc/OAc, and the four 1-MDT-bearing prodrugs
using the shake flask method, and platinum concentrations
were measured by ICP−MS analysis (Table 2). Log D7.4 was
chosen due to the fact that our platinum(IV) prodrugs possess
charged moieties (NH3
+ or COO−) at physiological pH, and
consequently, a direct comparison is only meaningful in
buffered solution. The log D7.4 obtained for oxaliplatin (−1.30)
is in good agreement with the log P-value reported in literature
(−1.39).44 The data for the 1-MDT-bearing prodrugs reveal
that the free carboxylic acid (log D7.4: SucEs/IdoCa at −2.02;
SucCa/IdoCa at −1.49) results in distinctly higher hydro-
philicity compared to the two analogues with a free amino
group (log D7.4: SucEs/IdoEs at −0.30; SucCa/IdoEs at
−0.16). However, as the cellular uptake of the four 1-MDT-
bearing complexes is quite similar (Figure 4), lipophilicity as
an important parameter for the drug uptake can be widely
excluded.
In general, the mode of uptake of the diverse platinum drugs
is heavily discussed in the literature. In case of oxaliplatin, it is
currently assumed that the drug enters the cancer cells mainly
via active organic cation/carnitine transporter OCT1 and
OCT2.45 Therefore, one explanation for the differences in the
uptake of oxaliplatin and the novel platinum(IV) complexes
could be a different recognition of the drugs by these uptake
mechanisms. However, as all 1-MDT-bearing compounds
enter the cells at similar efficiency, this indicates, on the one
hand, that the difference in cytotoxicity between the 1-MDT-
bearing drugs is not based on different drug uptake
mechanisms. On the other hand, as oxaliplatin is accumulating
Figure 4. Cellular platinum levels in HCT116 cells after 3 h
incubation with 20 μM of the compounds measured by ICP−MS.
Blanks (treated wells without cells) were subtracted from each value.
Bars indicate mean ± SD of triplicates. Significance was calculated
compared to the OAc/OAc mean value using an unpaired t-test (two-
tailed).
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with much higher potency, this suggests that the reduction
(and thus oxaliplatin release) is an intracellular process.
Selection of an IDO-Expressing Cancer Cell Model for
IDO Inhibition Studies. In order to select an appropriate cell
model for the analysis of the IDO-inhibitory potency of our
new platinum(IV) prodrugs, as a first step we tested a panel of
13 cell lines from human and murine origin for their IDO
messenger RNA (mRNA) levels by the real-time polymerase
chain reaction (Figure S8). In agreement with the literature,
SKOV3 ovarian carcinoma cells possessed very high IDO
expression.16,46 Also, one patient-derived melanoma model
VM7, which was established at our institute,47 was moderately
positive for IDO expression. Unfortunately, of the tested
murine colon cancer models, only CT-26 displayed some IDO
mRNA levels, while all others were negative. Subsequently, we
tested SKOV3 and VM7 for their sensitivity to our compound
panel. Noteworthy, both cell models are characterized by a
very low proliferation doubling time (Figure S9). Con-
sequently, it is not surprising that both cell models were
rather unresponsive to platinum treatment after 72 h (Table
S3) as such anticancer drugs generally require a longer
incubation time to show effects in slowly growing cancer
cells.48 Thus, we extended the incubation time of our
experiments with SKOV3 cells to 168 h and assessed the cell
number using crystal violet stain. As expected, this effectively
increased anticancer activity, especially for the platinum(IV)
prodrugs (Figure 5). In line with the results in the colon cancer
cell models, the less stable SucCa/IdoEs and SucEs/IdoEs
derivatives showed higher (and more rapidly emerging)
anticancer activity, resulting in lower IC50 values. All
subsequent studies on the IDO inhibition of the new
compounds were performed in SKOV3 cells.
Kinetics of 1-MDT Release in SKOV3 Lysates. In order
to determine whether our compounds are efficiently reduced
and thereby release 1-MDT inside cancer cells, the succinimide
prodrugs were incubated in SKOV3 lysates at 37 °C.
Subsequently, at various time points up to 72 h, proteins
were precipitated by addition of cold methanol (MeOH), and
the supernatant was analyzed by liquid chromatography−mass
spectrometry (LC−MS). We could nicely observe the released
1-MDT ligand (main fragment m/z = 202; [M − NH2]+;
Figure 6A). However, we plotted the reduction of the peak
intensities of the intact platinum(IV) complexes over time
because of the limited solubility of 1-MDT in MeOH, leading
to quantification problems. In line with the other results, the
data revealed that the 1-MDT ester-linked complexes were
reduced to a much higher extent than their 1-MDT-carbamato-
counterparts. After 72 h, nearly 100% 1-MDT release was
observed for SucEs/IdoEs and SucCa/IdoEs, whereas both,
SucEs/IdoCa and SucCa/IdoCa, were still present as
platinum(IV) species to ∼50% (Figure 6B). These results
not only support the hypothesis that the reduction-mediated 1-
MDT release is an intracellular event but also indicate that it is
not dependent on intact cells.
IDO Inhibition in Cell Culture. As already mentioned in
the introduction section, the enzymatic activity of IDO leads to
the catabolism of Trp to Kyn.7 To evaluate the activity of IDO
after treatment with our platinum(IV) complexes, Kyn levels
were analyzed in the supernatants of SKOV3 cells using a
colorimetric method and liquid chromatography−high reso-
lution mass spectrometry (LC−HRMS).49 As a first step, the
assays were performed with the supernatants collected after 72
h treatment with both 1-MT enantiomers (1-MDT and 1-
MLT). Noteworthy, due to their very poor cell permeability,
for both drugs, very high concentrations are usually applied (2
mM).50,51 Moreover, although 1-MDT has better immuno-
modulatory properties in vivo, 1-MLT is the stronger IDO
inhibitor in vitro.10 In good agreement with the literature,
strong reductions in Kyn levels were observed with 1-MLT,
while 1-MDT had borderline activity (Figure S10). As the
LC−HRMS data indicated that serum-containing medium has
already rather high Trp levels per se (data not shown), we
subsequently used a modified setting for the investigation of
our platinum(IV) drugs. In more detail, the cells were
incubated with the drugs for 72 h under normal cell culture
conditions. Then, the medium containing the test drugs and
10% FCS was replaced by serum-free medium for additional 24
h, which was then used for the measurements. Drug treatment
had no impact on cell viability at the used concentrations of 50
μM (data not shown). Corresponding to the accelerated 1-
MDT release, both fast-reducing compounds (SucEs/IdoEs
and SucCa/IdoEs) showed stronger inhibition of IDO and
therefore lower Kyn levels than the platinum(IV) reference
complexes or the slow 1-MDT-releasing derivatives (SucEs/
IdoCa and SucCa/IdoCa) (Figure 7A). The results were
confirmed by LC−HRMS measurements of Kyn, Trp, and
kynurenic acid, a downstream metabolite of the IDO pathway
(Figure 7B−D).52 In addition, these data nicely show the
metabolic connection between Kyn, Trp, and kynurenic acid:
the stronger the IDO inhibition, the lower the Kyn and
kynurenic acid levels and the higher the accumulation of Trp.
Noteworthy, the IDO inhibition of the two fast-reducing
compounds was superior even to 1-MLT, which is especially
interesting considering that the free IDO inhibitors were
applied at a dose of 2 mM, compared to the release of max. 50
μM inhibitor in case of the platinum(IV) prodrugs.
Consequently, these experiments not only confirm the release
Table 2. log D7.4-Values for Selected Complexes
oxaliplatin OAc/OAc SucEs/IdoCa SucCa/IdoCa SucEs/IdoEs SucCa/IdoEs
−1.30 −1.86 −2.02 −1.49 −0.30 −0.16
Figure 5. Long-term cytotoxicity assay in SKOV3 cancer cells. (A)
Cells were treated with increasing concentrations of the indicated
drugs for 168 h, fixed using ice-cold methanol, stained with crystal
violet, and fluorescence intensity was measured. Fluorescence
intensity was blotted as a full dose−response curve to calculate IC50
values. (B) Mean IC50 values given as mean ± SD.
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of functional 1-MDT from our new multi-modal complexes but
also show that coupling to a platinum(IV) center is a very
efficient way to enhance the transport of 1-MDT into cancer
cells, where it is released after intracellular reduction.
Tissue and Organ Distribution of the Maleimide-
Conjugated Drugs in Vivo. In order to investigate the
impact of the reduction kinetics on the pharmacological
behavior of the drugs in the living organism, as a next step,
SKOV3-bearing SCID mice were treated with our test
compound panel at concentrations equimolar to 9 mg/kg
oxaliplatin. After 24 h, the animals were sacrificed, and plasma,
tumor, and organ samples were collected and snap-frozen in
liquid nitrogen. Subsequently, platinum levels were analyzed by
ICP−MS after microwave digestion. With regard to blood
plasma, treatment with all maleimide derivatives led to
distinctly higher platinum concentrations than oxaliplatin or
OAc/OAc (∼12-fold in case of MalEs/IdoCa and MalCa/
IdoCa). Noteworthy, there were also distinct differences
between the fast- and the slow-reducing derivatives. Thus, the
animals treated with the two fast-reducing derivatives had
distinctly lower platinum levels (1.9 and 3.7 mg/kg forMalCa/
IdoEs and MalEs/IdoEs, respectively) than the two slow-
Figure 6. Reduction kinetics and release of 1-MDT in SKOV3 cell lysates. (A) Exemplary extracted ion chromatogram of 1-MDT release (m/z =
202) from SucCa/IdoEs (m/z = 843) after 24 h incubation. (B) Reduction kinetics of all succinimide complexes in SKOV3 cell lysates at 37 °C. At
0, 4, 24, and 72 h, methanol extracts were measured by HPLC with UV detection at 230 nm, as described in the experimental section. Data were
normalized to the area under curve of the respective platinum(IV) complex at t = 0.
Figure 7. Inhibition of the enzymatic IDO activity of SKOV3 cells in vitro. (A) Colorimetric Kyn detection assay in serum-free supernatant of
SKOV3 cells and LC−HRMS measurements of (B) Kyn, (C) Trp, and (D) kynurenic acid level normalized to cell number. Bars depict mean ± SD
of five replicates normalized to cell number. LOD = limit of detection. Significance was calculated in comparison to control conditions by multiple
comparison analysis [one-way analysis of variance (ANOVA)] and Dunnett post-hoc-test (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p <
0.0001).
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reducing drugs (5.9 and 6.4 mg/kg for MalEs/IdoCa and
MalCa/IdoCa, respectively) (Figure 8A). Subsequently,
especially the slow-reducing drugs showed pronounced
tumor accumulation in comparison to both of the reference
platinum complexes (Figure 8B−F). Noteworthy, as can be
seen in the oxaliplatin- and OAc/OAc-treated animals, the
malignant tissue is usually characterized by rather low drug
levels resulting, for example, in tumor to organ ratios of ∼0.3 in
case of the liver and kidney, respectively (Table S4). This ratio
was distinctly improved by the albumin-targeted prodrug
concept. Thus, especially in case of the slow-reducing agents,
tumor to organ ratios of 0.7 and 1.2 for the liver and kidney,
respectively, were observed. Overall, the impact of the albumin
targeting on drug distribution is congruent with previous
observations, as it results in a distinctly prolonged plasma half-
life together with preferential uptake by the tumor tissue.29,53
However, the plasma levels detected for our new drugs were
lower, when compared to data on oxaliplatin-releasing
platinum(IV) maleimide derivatives without the 1-MDT
ligand.29 This suggests that the additional 1-MDT moiety
might lead to enhanced clearance of the albumin conjugate or
faster reduction/oxaliplatin release. Whether this is specific to
IDO-containing compounds or a general phenomenon for
multi-modal maleimide derivatives needs to be addressed in
subsequent studies.
Anticancer and Immunomodulatory Activity against
CT26 Colon Cancer Tumors in Vivo. As a first step, to gain
more insights into the release of 1-MDT and subsequent IDO
inhibition in vivo, the slow-reducing MalEs/IdoCa and the
fast-reducing MalCa/IdoEs derivative were compared 24 h
after treatment. To this end, the tumors were harvested and
spiked with 13C-labeled metabolites. Tumor sample aliquots
were 5-fold concentrated and the metabolites (Figure S11A)
quantified by LC−HRMS. The relative quantification of 1-
MDT in the SKOV3 tumor tissue revealed a significant 1-
MDT release with both drugs. In good agreement with the
ICP−MS data, the 1-MDT levels were ∼2-fold higher in the
tumors of MalEs/IdoCa-treated animals than upon MalCa/
IdoEs treatment (Figure S11B). Accordingly, the application
of MalEs/IdoCa resulted in inhibition of IDO activity
indicated by an improved Trp to Kyn ratio compared to
solvent- or MalCa/IdoEs-treated animals (Figure S11C).
Interestingly, when looking at the IDO downstream catabolite
kynurenic acid (Figure S11D), enhanced signals were detected
in the MalCa/IdoEs-treated tumors. This supports the
hypothesis that slow-reducing maleimide derivatives are
characterized by an enhanced plasma-half-life, which results
in a prolonged IDO-inhibitory potential in vivo.
Next, we were interested in the in vivo anticancer activity of
our maleimide-containing compound panel. However, as both
IDO inhibition and oxaliplatin need an active immune system
for their activity against tumor cells, for these experiments, a
switch to an immune-competent model was necessary.
Therefore, we chose CT26 colon cancer allografts which
expressed the “highest” IDO levels among the tested murine
cell models (Figure S8B). The applied drug doses were
equimolar to the maximal tolerated dose of oxaliplatin (9 mg/
kg). In the first experiment, we compared the slow-reducing
MalCa/IdoCa with the fast-reducing MalCa/IdoEs (Figure
9A). Both compounds had significant anticancer activity, which
resulted in distinctly reduced tumor burden. However,MalCa/
IdoCa was superior in its activity against the CT26 tumors
Figure 8. Plasma levels and drug distribution in vivo. SKOV3-bearing male SCID mice were treated once via the tail vein with the indicated drugs at
doses equimolar to 9 mg/kg oxaliplatin. After 24 h, animals were sacrificed, and plasma (A), tumor tissue (B), and diverse organs (C−F) were
collected. Platinum levels in isolated tissues were detected by ICP−MS and normalized to tissue weight. Significance was calculated by ordinary
one-way ANOVA and Tukey’s multiple comparisons test (*p < 0.05, **p < 0.01, and ***p < 0.001).
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compared to MalCa/IdoEs and led to a prolonged period of
disease stabilization in all mice (tumor volumes of the
individual animals and Kaplan−Meier curves for overall
survival of the animals are shown in Figure S12). Subsequently,
we also tested MalEs/IdoEs (Figure S13A), which was
inactive, and MalEs/IdoCa (Figure S13B), which had activity
comparable to MalCa/IdoCa. Finally, MalCa/IdoCa activity
was directly compared to oxaliplatin (Figure S14). This
experiment clearly indicates that MalCa/IdoCa was superior
to oxaliplatin with respect to both, impact on tumor growth
and overall survival. Taken together, these initial experiments
indicate that slow platinum(IV) reduction kinetics (which in
cell culture experiments results in low activity) are very
beneficial in the in vivo setting, resulting in prolonged plasma
half-life, enhanced tumor accumulation, and superior anti-
cancer activity.
Finally, we were interested whether treatment with an 1-
MDT-releasing platinum(IV) drug leads to a changed immune
infiltration into CT26 tumors. To this end, flow cytometry of
immune cells isolated from tumor tissue and from tumor-
draining lymph nodes was performed 24 h after single
treatment with MalEs/IdoCa (Figure 9B). Indeed, therapy
led to a significant shift in the ratio of CD4+ (immunosup-
pressive) to CD8+ (immunostimulatory) T cells in the
malignant tissue. This was based on a significant increase in
the population of cytotoxic T cells, while there was a trend
toward a reduced number of FoxP3+ (immunosuppressive)
regulatory T cells (Treg). In contrast, drug treatment had no
effect on the immune cell population in the respective tumor-
draining lymph nodes. This indicates that the new drug indeed
has the potential to reactivate the immune system inside the
malignant tissue in a tumor-specific manner.
In order to investigate whether our prodrugs are also able to
provoke a comparable immune response in human cells, we
performed a series of co-culture experiments using isolated
peripheral blood mononuclear cells (PBMCs) from three
different healthy donors. Treg differentiation and expansion
were induced by co-culturing PBMCs and SKOV3 tumor cells
for 5 days in the presence of Treg differentiation medium
[interleukin 2 (IL-2), CD3, and transforming growth factor β
(TGFβ)] and nontoxic concentrations of oxaliplatin (10 μM),
1-MDT (50 μM), or SucEs/IdoCa (50 μM). Subsequently,
the frequency of Treg was assessed using multicolor flow
cytometry (Figure 9C). Of note, in all three individuals,
Figure 9. Anticancer activity and impact on tumor-infiltrating T-cell populations of our new 1-MDT-releasing drugs against CT26 allografts in
immune-competent Balb/c mice. (A) Schematic timeline of the performed therapy experiment in CT26-bearing Balb/c mice. Tumor growth was
measured daily by caliper after cell injection. Black arrows indicate treatments of solvent, MalCa/IdoEs or MalCa/IdoCa (iv) equimolar to 9 mg/
kg oxaliplatin. Significance was calculated in comparison to the solvent group by two-way ANOVA, multiple comparison analysis, and Bonferroni
post-hoc-test. (B) CT26-bearing Balb/c mice were treated once with drug doses ofMalEs/IdoCa equimolar to 9 mg/kg oxaliplatin via the tail vein.
After 24 h, animals were sacrificed, and tumors and tumor-draining lymph nodes were collected and analyzed for their T-cell populations by
multicolor flow cytometry (FC). Significance was calculated in comparison to the solvent group and within each group by unpaired t-test (two-
tailed) (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001). (C) Schematic representation of the Treg differentiation assay using a human
PBMC/SKOV3 tumor cell co-culture model. (D) Relative frequency of Treg in live CD4
+ T cells (CD45+ CD3+ CD4+) from a co-culture with
PBMC and SKOV3 tumor cells for oxaliplatin (10 μM), 1-MDT (50 μM), and SucEs/IdoCa (50 μM). Each value is normalized to control, and
values from the same donor are presented in the same color (black, orange, or pink). Significance was calculated using one-way ANOVA with
Dunnett’s multiple comparison tests.
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SucEs/IdoCa was superior to oxaliplatin or 1-MDT treatment
and significantly reduced Treg differentiation (Figure 9D). This
suggests that through introduction of 1-MDT as a bioactive
ligand, our prodrugs effectively reduced the amounts of tumor-
suppressive Treg also in a human co-culture setting.
■ CONCLUSIONS
During the last few decades, there is increased understanding
that the malignant tissue differs from healthy organs in
multiple aspects.54,55 Consequently, it is not only of interest to
develop new drugs with better tumor-targeting properties but
also to consider the changed tumor microenvironment for
tumor-specific therapy (e.g., the tumor-promoting state of the
immune cell population). This study reports on the first triple-
action prodrugs of oxaliplatin, which is the current state of the
art therapy against colon cancer.2 To this end, we used well-
established platinum(IV) prodrugs (which themselves have
often insufficient targeting properties due to premature
activation in e.g. red blood cells) and improved their tumor
delivery by attaching an albumin-targeting maleimide moiety as
one axial ligand. Albumin is efficiently taken up und degraded
by cancer cells due to their enhanced needs for nutrients.25 In
the second axial position, the clinically investigated IDO
inhibitor 1-MDT was attached.8 This approach results in the
tumor-specific release of the immunomodulator together with
oxaliplatin after activation by reduction inside the cancer cell.
In order to allow the selection of the best lead candidate for
further (pre)clinical development, we prepared several
derivatives, where 1-MDT has been attached to the molecules
via different strategies. Noteworthy, these derivatives distinctly
differed in their reduction behavior (fast reducing SucEs/
IdoEs and SucCa/IdoEs; slow-reducing SucEs/IdoCa and
SucCa/IdoCa). Overall, the low reductive stabilities observed
for the SucEs/IdoEs and SucCa/IdoEs complexes were highly
unexpected as similar oxaliplatin-based platinum(IV) com-
plexes exhibit high reductive inertness.29,40−42 Subsequent
analysis indeed confirmed that the complexes not only release
(as expected) unmodified 1-MDT but also confirmed that this
process has to be intracellular. This indicates that the coupling
to a platinum(IV) center is also an efficient approach to deliver
1-MDT (which has rather low cell permeability) into cancer
cells. Noteworthy, cell culture is rather limited when it comes
to prediction of in vivo anticancer activity. This is especially
true in case of maleimide-targeted drugs, as the moiety is not
only prone to hydrolysis but also reacts with components of
the cell culture medium (e.g. free cysteine). Moreover, cancer
cells are usually “overfed” in the standard cell culture
conditions, which can reduce their albumin uptake and
catabolism. Consequently, in vivo experiments in tumor-
bearing mice were performed to gain preliminary information
on pharmacokinetic, immunomodulatory potential, and
anticancer activity. In general, there are two basic screening
approaches: on the one hand, human cancer cells can be tested
in immune-deficient mice. On the other hand, immune-
competent mice carrying murine allograft tumors can be used.
For oxaliplatin prodrugs, immune-competent models are
important, as it is well-known that the activity is dependent
on the immune system.3 Consequently, anticancer activity and
impact on tumor selectivity of the immune-inhibitory potential
were tested in CT26 allografts. These investigations impres-
sively confirm that there is no direct correlation between cell
culture data and in vivo activity. The IdoEs complexes show
higher activity in cell culture (due to faster reduction),
however, lower activity in mice. In turn, the IdoCa compounds
(with slower reduction) are widely inactive in common 48 h or
72 h viability assays but reveal higher tumor-inhibiting
potential in vivo. The animal experiments also show that
these complexes are able to inhibit IDO in the malignant
tissue, which leads to tumor-specific changes in the T-cell
population. However, our data also indicate that for the final
selection of a lead candidate, further studies are required as our
preliminary data reveal that the four 1-MDT-releasing
derivatives differ in their pharmacological behavior (e.g.,
plasma half-life). The exact reasons for these effects need to
be further dissected and more in-depth studies are necessary to
establish the best therapeutic scheme (e.g., maximal tolerable
dose and frequency of the treatment) for most favorable IDO
inhibition.
In summary, in this study, we demonstrate that the design of
albumin-targeted multi-modal prodrugs on platinum(IV) basis
is a promising strategy to enhance the intracellular uptake of
compounds with low cell permeability and additionally to
improve their selective delivery into the malignant tissue. This
should allow tumor-specific anticancer therapy supported by a
favorable immune microenvironment.
■ EXPERIMENTAL SECTION
Synthesis. Materials and Methods. Potassium tetrachloridopla-
tinate was purchased from Johnson Matthey (Switzerland). Water for
synthesis was taken from a reverse osmosis system and distilled twice
before use. For HPLC measurements, Milli-Q water (18.2 MΩ·cm,
Merck Milli-Q Advantage, Darmstadt, Germany) was used.
Compound 5a, other chemicals, and solvents were purchased from
commercial suppliers (Sigma-Aldrich, Merck, Acros, Fluka, and Fisher
Scientific). Oxaliplatin, complexes 7a, 7b, OAc/OAc, and 3-(1-
methyl-1H-indol-3-yl)propanoic acid (IPA) were synthesized similar
to methods described in the literature.38,39,56,57 Electrospray
ionization (ESI) mass spectra were recorded on a Bruker amaZon
SL ion trap mass spectrometer in the positive and/or negative mode
by direct infusion at the Mass Spectrometry Centre of the University
of Vienna. One- and two-dimensional 1H and 13C spectra were
recorded on a Bruker AV Neo 500 or AV III 600 spectrometer at 298
K. For 1H and 13C NMR spectra, the solvent residual peak was taken
as an internal reference. The 1H and 13C NMR spectra of the final
compounds are depicted in Figures S17−S24. Purification by
preparative reverse phase (RP) HPLC was performed on an Agilent
1200 series system using a Waters XBridge C18 column (19 × 250
mm). Elemental analysis measurements were carried out on a
PerkinElmer 2400 CHN elemental analyzer at the Microanalytical
Laboratory of the University of Vienna and are within ±0.4%,
confirming >95% purity. Of course, the content of TFA and water can
vary between different batches of the same compound. In addition,
UHPLC chromatograms of the final compounds can be seen in
Figures S25−S32. For NMR numbering of the final compounds, see
Scheme S1.
General Procedure A for Isocyanate Formation from Carboxylic
Acids. The carboxylic acid was dissolved in anhydrous toluene, and
1.2 equiv of TEA was added. DPPA (1 equiv) was slowly added, and
the mixture was stirred under Ar at RT for 5.5 h. A saturated
NaHCO3 solution was added to the mixture, the phases were
separated, and the organic layer was washed with brine, dried over
Na2SO4, filtered, and subsequently refluxed under Ar for 17 h. The
solvents were removed in vacuo to obtain the crude isocyanate which
was used without further purification.
tert-Butyl 1-Methyl-D-tryptophanate (1). 1-MDT (500 mg, 2.29
mmol) was suspended in tert-butyl acetate (10 mL) and cooled to 0
°C. Perchloric acid (60%) (0.38 mL, 3.43 mmol, 1.5 equiv) was added
slowly, and the reaction mixture was stirred at RT for 19 h. 0.5 M HCl
(4 × 30 mL) was added to the reaction mixture, and the phases were
separated. The combined aqueous layers were basified to pH 9−10 by
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addition of 10% K2CO3 solution, extracted with DCM (4 × 50 mL),
dried over MgSO4, and evaporated to dryness to obtain 1 (244 mg,
38%) as a colorless oil. 1H NMR (500 MHz, DMSO-d6): δ 7.53 (d, J
= 7.9 Hz, 1H), 7.36 (d, J = 8.2 Hz, 1H), 7.15−7.07 (m, 2H), 7.02−
6.98 (m, 1H), 3.72 (s, 3H), 3.47 (t, J = 6.4 Hz, 1H), 2.95 (dd, J =
14.2, 6.3 Hz, 1H), 2.85 (dd, J = 14.2, 6.7 Hz, 1H), 1.74 (br s, 2H),




nate (2). 1,1′-Carbonyldiimidazole (249 mg, 1.54 mmol, 2 equiv)
was dissolved in DCM (10 mL), and DIPEA (0.34 mL, 1.92 mmol,
2.5 equiv) was added. 1 (211 mg, 0.77 mmol, 1 equiv) was slowly
added to the solution and stirred at RT for 4 h. The reaction mixture
was washed with half-saturated aqueous NH4Cl solution, and the
organic phase was dried over MgSO4 and evaporated to dryness. The
crude product was purified by flash column chromatography (40%
hexane in EtOAc) to obtain title compound 2 (150 mg, 52%) as a
white solid. 1H NMR (500 MHz, DMSO-d6): δ 8.86 (d, J = 7.6 Hz,
1H), 8.24 (m, 1H), 7.69 (t, J = 1.4 Hz, 1H), 7.58 (d, J = 7.9 Hz, 1H),
7.38 (d, J = 8.2 Hz, 1H), 7.19 (s, 1H), 7.15−7.11 (m, 1H), 7.05−7.00
(m, 2H), 4.47 (ddd, J = 9.5, 7.6, 5.6 Hz, 1H), 3.72 (s, 3H), 3.27 (dd, J
= 14.6, 5.5 Hz, 1H), 3.17 (dd, J = 14.6, 9.4 Hz, 1H), 1.34 (s, 9H). MS
(m/z): calcd for C20H24N4O3Na (M + Na)
+, 391.17; found, 391.19.
Nα-(tert-Butoxycarbonyl)-1-methyl-D-tryptophan (4). 1-MDT
(500 mg, 2.29 mmol) was suspended in H2O/dioxane 1:1 (12 mL).
NaOH (229 mg, 5.73 mmol, 2.5 equiv) was added. Di-t-butyl
dicarbonate was dissolved in H2O/dioxane 1:2 (2 mL) and added to
the aforementioned solution. The reaction mixture was stirred at RT
for 4 h, poured into H2O (25 mL), adjusted to pH 2 with 1 M HCl,
and extracted with EtOAc (3 × 25 mL). The organic layers were
combined, washed with brine, dried over NaSO4, and evaporated to
dryness to give 4 (524 mg, 71%) as a white powder. 1H NMR (500
MHz, CDCl3): δ 7.59 (d, J = 7.9 Hz, 1H), 7.29 (d, J = 8.2 Hz, 1H),
7.23 (t, J = 7.6 Hz, 1H), 7.11 (t, J = 7.5 Hz, 1H), 6.92 (s, 1H), 5.08−
4.96 (m, 1H), 4.70−4.44 (m, 1H), 3.75 (s, 3H), 3.37−3.26 (m, 2H),
1.43 (s, 9H). MS (m/z): calcd for C17H21N2O4 (M − H)−, 317.15;
found, 316.93.
6-(2,5-Dioxopyrrolidine-1-yl)hexanoic Acid (5b). Succinic anhy-
dride (2.0 g, 20.0 mmol) was suspended in acetic acid (30 mL), and
6-aminohexanoic acid (2.62 g, 20.0 mmol, 1 equiv) was added. The
reaction mixture was refluxed for 3 h, and the solvent was removed in
vacuo. The crude product was purified by flash column chromatog-
raphy (20% hexane in EtOAc) to obtain 5b (2.46 g, 57%) as a white
solid. 1H NMR (500 MHz, CDCl3): δ 3.54−3.47 (m, 2H), 2.70 (s,
4H), 2.35 (t, J = 7.4 Hz, 2H), 1.70−1.63 (m, 2H), 1.63−1.55 (m,
2H), 1.40−1.31 (m, 2H). MS (m/z): calcd for C10H15NO4Na (M +
Na)+, 236.09; found, 236.07.
1-(5-Isocyanatopentyl)-1H-pyrrole-2,5-dione (6a). Compound 6a
was synthesized according to general procedure A using 6-
maleimidohexanoic acid (1.0 g, 4.73 mmol), toluene (25 mL), TEA
(0.79 mL, 5.68 mmol), and DPPA (1.07 mL, 4.97 mmol). Yield: 1.10
g of crude colorless oil. 1H NMR (500 MHz, CDCl3): δ 6.69 (s, 2H),
3.53 (t, J = 7.2 Hz, 2H), 3.30 (t, J = 6.6 Hz, 2H), 1.67−1.59 (m, 4H),
1.42−1.33 (m, 2H).
1-(5-Isocyanatopentyl)pyrrolidine-2,5-dione (6b). Compound 6a
was synthesized according to general procedure A using 5b (1.0 g,
4.69 mmol), anh. toluene (40 mL), TEA (0.78 mL, 5.63 mmol, 1.2
equiv), and DPPA (1.01 mL, 4.69 mmol, 1 equiv). Yield: 0.92 g of
crude colorless oil. 1H NMR (500 MHz, DMSO-d6): δ 3.36−3.31 (m,
4H), 2.61 (s, 4H), 1.58−1.51 (m, 2H), 1.51−1.43 (m, 2H), 1.30−
1.22 (m, 2H).
(OC-6-34)-[(1R,2R)-1,2-Cyclohexanediamino][5-(2,5-dioxo-2,5-
d i h y d r o - 1 H - p y r r o l - 1 - y l ) p e n t y l c a r b a m a t o ] -
hydroxidooxalatoplatinum(IV) (8a). 7 (555 mg, 1.29 mmol) was
suspended in anh. DMSO (50 mL). A solution of 6a (268 mg, 1.29
mmol, 1 equiv) in anh. DMSO (1 mL) was added to the mixture over
a period of 16 h with the help of a syringe pump. The reaction
mixture was stirred further at RT for 3 h, and the solvent was removed
in vacuo at 50 °C. MeOH was added, and the crude product
precipitated by addition of methyl tert-butyl ether. The resulting white
powder (680 mg) was used without further purification. For
characterization purpose, a small fraction was purified via preparative
RP-HPLC [16% acetonitrile (MeCN) (+0.1% HCOOH) in H2O
(+0.1% HCOOH); isocratic]. 1H NMR (500 MHz, DMSO-d6): δ
10.00−9.57 (m, 1H), 8.28 (br s, 1H), 7.64 (br s, 1H), 7.07 (br s, 1H),
7.00 (s, 2H), 6.41−6.01 (m, 1H), 2.94−2.73 (m, 2H), 2.59−2.51 (m,
2H), 2.26 (br s, 1H), 2.13−2.00 (m, 2H), 1.55−1.22 (m, 8H), 1.20−




d i h y d r o - 1 H - p y r r o l i d i n - 1 - y l ) p e n t y l c a r b am a t o ] -
hydroxidooxalatoplatinum(IV) (8b). 7 (200 mg, 0.46 mmol) was
suspended in anh. DMSO (2.5 mL). A solution of 6b (97 mg, 0.46
mmol, 1 equiv) in anh. DMSO (1 mL) was added to the mixture over
a period of 17 h with the help of a syringe pump. The reaction
mixture was stirred further at RT for 3 h, the solvent was removed in
vacuo at 50 °C, and the crude product was purified by preparative RP-
HPLC [12% MeCN (+0.1% TFA) in H2O (+0.1% TFA); isocratic]
to obtain title compound 8b (117 mg, 36%) as a white powder. 1H
NMR (500 MHz, DMSO-d6): δ 10.04−9.40 (m, 1H), 8.80−8.11 (m,
1H), 7.89−7.54 (m, 1H), 7.17−6.93 (m, 1H), 6.47−5.90 (m, 1H),
3.31 (t, J = 7.1 Hz, 2H), 2.92−2.74 (m, 2H), 2.61 (s, 4H), 2.57−2.52
(m, 2H), 2.17−1.99 (m, 2H), 1.56−1.23 (m, 8H), 1.21−1.06 (m,





hydroxidooxalatoplatinum(IV) (9). In a dry flask, 2 (140 mg, 0.38
mmol) was dissolved in anh. DMSO (1.5 mL) and stirred under Ar at
85 °C for 5 h in order to obtain isocyanate 3. The reaction mixture
was cooled to RT and added to a suspension of 7 (164 mg, 0.38
mmol, 1 equiv) in anh. DMSO (1.5 mL) over a period of 17 h with
the help of a syringe pump. The solvent was removed in vacuo at 50
°C, and the crude product was purified by preparative RP-HPLC
[38% MeCN (+0.1% HCOOH) in H2O (+0.1% HCOOH);
isocratic] to obtain 9 (70 mg, 25%) as a yellow solid. 1H NMR
(500 MHz, DMSO-d6): δ 9.79−9.40 (m, 1H), 8.21 (br s, 1H), 7.66
(br s, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.37 (d, J = 8.2 Hz, 1H), 7.16−
6.98 (m, 4H), 6.36−6.01 (m, 1H), 4.28−4.04 (m, 1H), 3.73 (s, 3H),
2.99 (d, J = 6.8 Hz, 2H), 2.55−2.52 (m, 2H), 2.36 (s, 1H), 2.13−1.99
(m, 2H), 1.54−1.39 (m, 3H), 1.32−1.19 (m, 10H), 1.17−0.99 (m,
2H). MS (m/z): calcd C25H36N4O9NaPt (M + Na)
+, 754.20; found,
754.21.
General Procedure B for t-Butyl- and Boc-Deprotection. The
protected complex was dissolved in DCM (∼40 mM), and 10% TFA
(v/v) was added. The reaction mixture was stirred at RT for 1 h, the





fluoroacetate (MalCa/IdoEs). 4 (169 mg, 0.53 mmol) was dissolved
in DMF (6 mL), and TEA (96 μL, 0.69 mmol, 1.3 equiv) and TBTU
(188 mg, 0.58 mmol, 1.1 equiv) were added. After 10 min at RT,
crude 8a (340 mg) was added and stirred further at RT for 17 h. The
solvent was evaporated under reduced pressure, and the crude
product was purified by preparative RP-HPLC [42% MeCN (+0.1%
HCOOH) in H2O (+0.1% HCOOH); isocratic] to obtain Boc-
MalCa/IdoEs (52 mg, 8% over two steps) as a yellow solid.
Deprotection was performed according to general procedure B
starting from Boc-MalCa/IdoEs (51 mg, 0.05 mmol). Preparative RP-
HPLC conditions: 28% MeCN (+0.1% TFA) in H2O (+0.1% TFA);
isocratic. Yield: 32 mg (58%) of yellow solid. 1H NMR (600 MHz,
DMSO-d6; for NMR numbering, see Scheme S1): δ 9.93−9.43 (m,
1H, DACH-1), 8.83−8.59 (m, 1H, DACH-1), 8.13−8.05 (br s, 1H,
DACH-1), 8.05−7.96 (m, 3H, IDO-14), 7.64−7.54 (m, 2H, 1×
DACH-1, IDO-5), 7.43 (d, J = 8.3 Hz, 1H, IDO-8), 7.21−7.15 (m,
1H, IDO-7), 7.13 (s, 1H, IDO-2), 7.07 (t, J = 7.4 Hz, 1H, IDO-6),
7.00 (s, 2H, MAL-3), 6.87 (t, J = 5.5 Hz, 1H, MAL-9), 4.16−4.08 (m,
1H, IDO-12), 3.75 (s, 3H, IDO-10), 3.35−3.28 (m, 3H, MAL-4, 1×
Journal of Medicinal Chemistry pubs.acs.org/jmc Article
https://doi.org/10.1021/acs.jmedchem.1c00770
J. Med. Chem. 2021, 64, 12132−12151
12143
IDO-11), 3.03 (dd, J = 15.2, 8.2 Hz, 1H, IDO-11), 2.89 (qd, J = 13.3,
6.4 Hz, 2H, MAL-8), 2.68−2.58 (m, 2H, DACH-2), 2.18 (d, J = 11.2
Hz, 1H, DACH-3), 2.09 (d, J = 9.7 Hz, 1H, DACH-3), 1.53 (d, J =
11.6 Hz, 2H, 2× DACH-4), 1.50−1.39 (m, 4H, MAL-5, 2× DACH-
3), 1.36 (dt, J = 14.5, 7.1 Hz, 2H, MAL-7), 1.22−1.00 (m, 4H, 2×
DACH-4, MAL-6). 13C NMR (151 MHz, DMSO-d6): δ 174.1 (IDO-
13), 171.1 (2× MAL-2), 164.2 (MAL-10), 163.7, 163.7 (2× oxalate),
136.8 (IDO-9), 134.5 (2× MAL-3), 129.0 (IDO-2), 127.2 (IDO-4),
121.4 (IDO-7), 118.7 (IDO-6), 118.4 (IDO-5), 109.9 (IDO-8), 106.7
(IDO-3), 61.5, 60.3 (2× DACH-2), 53.1 (IDO-12), 40.7 (MAL-8),
37.0 (MAL-4), 32.4 (IDO-10), 31.00, 30.8 (2× DACH-3), 29.0
(MAL-7), 27.7 (MAL-5), 26.8 (IDO-11), 23.6, 23.6 (2× DACH-4),
23.4 (MAL-6). MS (m/z): calcd C30H40N6O10NaPt (M + Na)
+,
840.25; found, 840.24. EA calcd C30H40N6O10Pt·1.5TFA: C, 39.21;




(MalCa/IdoCa). In a dry flask, 9 (35 mg, 0.05 mmol) was dissolved in
anh. DMF (1 mL), and 6a (60 mg, 0.29 mmol, 6 equiv) was added.
The reaction mixture was stirred under Ar at RT for 18 h. The solvent
was evaporated in vacuo, and the crude product was purified by
preparative RP-HPLC [51% MeCN (+0.1% HCOOH) in H2O
(+0.1% HCOOH); isocratic] to obtain t-butyl MalCa/IdoCa (33
mg, 73%) as a yellow solid. Deprotection was performed according to
general procedure B starting from t-butyl MalCa/IdoCa (35 mg, 0.04
mmol). Preparative RP-HPLC conditions: 30% MeCN (+0.1% TFA)
in H2O (+0.1% TFA); isocratic. Yield: 19 mg (56%) of yellow solid.
1H NMR (600 MHz, DMSO-d6; for NMR numbering, see Scheme
S1): δ 9.80−9.44 (m, 1H, DACH-1), 9.25 (br s, 1H, DACH-1), 8.55
(br s, 1H, DACH-1), 8.31 (s, 1H, DACH-1), 7.48 (d, J = 7.9 Hz, 1H,
IDO-5), 7.36 (d, J = 8.2 Hz, 1H, IDO-8), 7.12 (t, J = 7.6 Hz, 1H,
IDO-7), 7.06 (s, 1H, IDO-2), 7.00 (t, J = 7.4 Hz, 1H, IDO-6), 6.97 (s,
2H, 2× MAL-3), 6.80−6.59 (m, 1H, MAL-9), 6.58−6.05 (m, 1H,
IDO-14), 4.31−4.12 (m, 1H, IDO-12), 3.73 (s, 3H, IDO-10), 3.36−
3.34 (m, 2H, MAL-4), 3.08 (dd, J = 14.8, 4.9 Hz, 1H, IDO-11), 3.02
(dd, J = 14.6, 7.8 Hz, 1H, IDO-11), 2.93−2.81 (m, 2H, MAL-8),
2.59−2.52 (m, 2H, 2× DACH-2), 2.18−2.09 (m, 2H, 2× DACH-3),
1.54−1.47 (m, 2H, 2× DACH-4), 1.47−1.41 (m, 2H, MAL-N-5),
1.41−1.26 (m, 4H, 2× DACH-3, MAL-7), 1.20−1.03 (m, 4H, 2×
DACH-4, MAL-6). 13C NMR (151 MHz, DMSO-d6): δ 174.0 (IDO-
13), 171.2 (MAL-2), 164.5 (MAL-10), 163.9 (IDO-15), 163.4
(oxalate), 136.6 (IDO-9), 134.5 (2× MAL-3), 128.1 (IDO-2), 127.6
(IDO-4), 121.2 (IDO-7), 118.7 (IDO-6), 118.5 (IDO-5), 109.7
(IDO-8), 109.2 (IDO-3), 61.1, 61.0 (2× DACH-2), 55.3 (IDO-12),
40.7 (MAL-8), 37.1 (MAL-4), 32.4 (IDO-10), 31.1 (DACH-3), 29.1
(MAL-7), 27.8 (MAL-5), 26.7 (IDO-11), 23.7 (MAL-6), 23.5, 23.5
(2× DACH-4). MS (m/z): calcd C31H40N6O12NaPt (M + Na)
+,
906.22; found, 906.22. EA calcd C31H40N6O12Pt·1.5H2O: C, 40.88;




IdoCa). 5a (11 mg, 0.05 mmol, 1.2 equiv) was dissolved in DMF
(1 mL). Subsequently, N-ethylmaleimide (28 mg, 0.23 mmol, 5
equiv), TEA (12.5 μL, 0.09 mmol, 2 equiv), and TBTU (22 mg, 0.07
mmol, 1.5 equiv) were added. After 15 min at RT, 9 (33 mg, 0.05
mmol, 1 equiv) was added and stirred further at RT for 17 h. The
solvent was evaporated under reduced pressure, and the crude
product was purified by preparative RP-HPLC [50% MeCN (+0.1%
HCOOH) in H2O (+0.1% HCOOH); isocratic] to yield t-butyl
MalEs/IdoCa (25 mg, 60%) as a yellow solid. Deprotection was
performed according to general procedure B starting from t-butyl
MalEs/IdoCa (25 mg, 0.03 mmol). Preparative RP-HPLC con-
ditions: 35% MeCN (+0.1% TFA) in H2O (+0.1% TFA); isocratic.
Yield: 19 mg (74%) of yellow solid. 1H NMR (600 MHz, DMSO-d6;
for NMR numbering, see Scheme S1): δ 12.57 (br s, 1H, IDO−
COOH), 9.27 (t, J = 9.4 Hz, 1H, DACH-1), 8.48 (br s, 1H, DACH-
1), 8.33 (br s, 1H, DACH-1), 8.25 (t, J = 9.7 Hz, 1H, DACH-1), 7.49
(d, J = 7.9 Hz, 1H, IDO-5), 7.37 (d, J = 8.2 Hz, 1H, IDO-8), 7.15−
7.10 (m, 1H, IDO-7), 7.07 (s, 1H, IDO-2), 7.04−6.99 (m, 1H, IDO-
6), 6.99 (s, 2H, MAL-3), 6.63−6.09 (m, 1H, IDO-14), 4.31−4.14 (m,
1H, IDO-12), 3.74 (s, 3H, IDO-10), 3.39−3.35 (m, 2H, MAL-4),
3.08 (dd, J = 14.6, 5.0 Hz, 1H, IDO-11), 3.03 (dd, J = 14.8, 7.8 Hz,
1H, IDO-11), 2.58−2.51 (m, 2H, 2× DACH-2), 2.29−2.18 (m, 2H,
MAL-8), 2.15−2.06 (m, 2H, 2× DACH-3), 1.53−1.46 (m, 2H, 2×
DACH-4), 1.46−1.36 (m, 5H, MAL-5, MAL-7, 1× DACH-3), 1.36−
1.27 (m, 1H, DACH-3), 1.20−1.07 (m, 4H, 2× DACH-4, MAL-6).
13C NMR (151 MHz, DMSO-d6): δ 180.8 (MAL-10), 173.8 (IDO-
13), 171.1 (2× MAL-2), 163.8 (IDO-15), 163.4, 163.3 (2× oxalate),
136.4 (IDO-9), 134.5 (2× MAL-3), 128.0 (IDO-2), 127.5 (IDO-4),
121.0 (IDO-7), 118.5 (IDO-6), 118.4 (IDO-5), 109.6 (IDO-8), 109.1
(IDO-3), 61.1, 60.9 (2× DACH-2), 55.2 (IDO-12), 36.9 (MAL-4),
35.5 (MAL-8), 32.3 (IDO-10), 30.9, 30.9 (2× DACH-3), 27.7 (MAL-
5), 26.6 (IDO-11), 25.6 (MAL-6), 24.8 (MAL-7), 23.5, 23.5 (2×
DACH-4). MS (m/z): calcd C31H39N5O12NaPt (M + Na)
+, 891.21;
found, 891.20. EA calcd C31H39N5O12Pt·0.5TFA·1H2O: C, 40.72; H,




tate (MalEs/IdoEs). 4 (203 mg, 0.64 mmol, 1.1 equiv) and 5a (135
mg, 0.64 mmol, 1.1 equiv) were dissolved in DMF (6 mL), and TEA
(242 μL, 1.73 mmol, 3 equiv) and TBTU (465 mg, 1.45 mmol, 2.5
equiv) were added. After 10 min at RT, 9 (250 mg, 0.58 mmol, 1
equiv) was added and stirred further at RT for 16 h. The solvent was
evaporated under reduced pressure, and the crude product was
purified by preparative RP-HPLC [gradient: 35−50% MeCN (+0.1%
HCOOH) in H2O (+0.1% HCOOH) over 20 min] to obtain Boc-
MalEs/IdoEs (140 mg, 52%) as a yellow solid. Deprotection was
performed according to general procedure B starting from Boc-
MalEs/IdoEs (140 mg, 0.15 mmol). Preparative RP-HPLC
conditions: 30% MeCN (+0.1% TFA) in H2O (+0.1% TFA);
isocratic. Yield: 104 mg (69%) of yellow solid. 1H NMR (600 MHz,
DMSO-d6; for NMR numbering, see Scheme S1): δ 8.57−8.40 (m,
1H, DACH-1), 8.36−8.24 (m, 1H, DACH-1), 8.24−8.13 (m, 1H,
DACH-1), 8.02 (br s, 3H, IDO-14), 7.68−7.51 (m, 2H, 1× DACH-1,
IDO-5), 7.43 (d, J = 8.3 Hz, 1H, IDO-8), 7.21−7.15 (m, 1H, IDO-7),
7.12 (s, 1H, IDO-2), 7.09−7.05 (m, 1H, IDO-6), 7.00 (s, 2H, MAL-
3), 4.14−4.04 (m, 1H, IDO-12), 3.75 (s, 3H, IDO-10), 3.38−3.36
(m, 2H, MAL-4), 3.33−3.32 (m, 1H, IDO-11), 3.03 (dd, J = 15.3, 8.3
Hz, 1H, IDO-11), 2.65−2.56 (m, 2H, 2× DACH-2), 2.32−2.22 (m,
2H, MAL-8), 2.21−2.13 (m, 1H, DACH-3), 2.10−2.02 (m, 1H,
DACH-3), 1.56−1.50 (m, 2H, 2× DACH-4), 1.50−1.39 (m, 6H,
MAL-5, MAL-7-, 2× DACH-3), 1.24−1.12 (m, 3H, MAL-6, 1×
DACH-4), 1.10−1.00 (m, 1H, DACH-4). 13C NMR (151 MHz,
DMSO-d6): δ 180.8 (MAL-10), 174.1 (IDO-13), 171.1 (2× MAL-2),
163.7, 163.7 (2× oxalate), 157.9, 157.7 (2× TFA), 136.8 (IDO-9),
134.5 (MAL-3), 129.0 (IDO-2), 127.2 (IDO-4), 121.4 (IDO-7),
118.7 (IDO-6), 118.4 (IDO-5), 109.9 (IDO-8), 106.7 (IDO-3), 61.5,
60.4 (2× DACH-2), 53.2 (IDO-12), 36.9 (MAL-4), 35.4 (MAL-8),
32.4 (IDO-10), 31.0, 30.8 (2× DACH-3), 27.7 (MAL-5), 26.7 (IDO-
11), 25.6 (MAL-6), 24.8 (MAL-7), 23.6, 23.5 (2× DACH-4). MS
(m/z): calcd C30H40N5O10Pt (M + H)
+, 825.24; found, 825.16. EA
calcd C30H39N5O10Pt·1.5TFA·0.5H2O: C, 39.45; H, 4.16; N, 6.97%.




Trifluoroacetate (SucCa/IdoEs). 4 (30 mg, 0.09 mmol) was dissolved
in DMF (2 mL), and TEA (20 μL, 0.14 mmol, 1.5 equiv) and TBTU
(33 mg, 0.10 mmol, 1.1 equiv) were added. After 10 min at RT, 8b
(60 mg, 0.09 mmol, 1 equiv) was added and stirred further at RT for
24 h. The solvent was evaporated under reduced pressure, and the
crude product was purified by preparative RP-HPLC [43% MeCN
(+0.1% HCOOH) in H2O (+0.1% HCOOH); isocratic] to obtain
Boc-SucCa/IdoEs (38 mg, 43%) as a yellow solid. Deprotection was
performed according to general procedure B starting from Boc-
SucCa/IdoEs (31 mg, 0.03 mmol). Preparative RP-HPLC con-
ditions: 30% MeCN (+0.1% TFA) in H2O (+0.1% TFA); isocratic.
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Yield: 17 mg (51%) of yellow solid. 1H NMR (600 MHz, DMSO-d6;
for NMR numbering, see Scheme S1): δ 9.93−9.47 (m, 1H, DACH-
1), 8.82−8.62 (m, 1H, DACH-1), 8.09 (br s, 1H, DACH-1), 8.02 (br
s, 3H, IDO-14), 7.67−7.56 (m, 2H, 1× DACH-1, IDO-5), 7.44 (d, J
= 8.3 Hz, 1H, IDO-8), 7.21−7.17 (m, 1H, IDO-7), 7.14 (s, 1H, IDO-
2), 7.08 (t, J = 7.4 Hz, 1H, IDO-6), 6.87 (t, J = 5.5 Hz, 1H, SUC-9),
4.18−4.07 (m, 1H, IDO-12), 3.76 (s, 3H, IDO-10), 3.34−3.31 (m,
3H, SUC-4, 1× IDO-11), 3.03 (dd, J = 15.2, 8.2 Hz, 1H, IDO-11),
2.96−2.84 (m, 2H, SUC-8), 2.68−2.58 (m, 6H, SUC-3, 2× DACH-
2), 2.19 (d, J = 11.2 Hz, 1H, DACH-3), 2.10 (d, J = 9.8 Hz, 1H,
DACH-3), 1.54 (d, J = 11.3 Hz, 2H, 2× DACH-4), 1.49−1.27 (m,
6H, SUC-5, 2× DACH-3, SUC-7), 1.23−1.02 (m, 4H, 2× DACH-4,
SUC-6). 13C NMR (151 MHz, DMSO-d6): δ 177.8 (SUC-2), 174.1
(IDO-13), 164.2 (SUC-10), 163.7, 163.7 (2× oxalate), 136.8 (IDO-
9), 129.0 (IDO-2), 127.2 (IDO-4), 121.4 (IDO-7), 118.7 (IDO-6),
118.4 (IDO-5), 109.8 (IDO-8), 106.7 (IDO-3), 61.4, 60.3 (2×
DACH-2), 53.1 (IDO-12), 40.7 (SUC-8), 37.8 (SUC-4), 32.4 (IDO-
10), 31.0, 30.8 (2× DACH-3), 29.1 (SUC-7), 28.0 (SUC-3), 26.9
(SUC-5), 26.8 (IDO-11), 23.6, 23.6 (2× DACH-4), 23.5 (SUC-6).
MS (m/z): calcd C30H42N6O10Pt (M + H)
+, 842.27; found, 842.28.
EA calcd C30H42N6O10Pt·1.5TFA·0.5H2O: C, 38.87; H, 4.20; N, 8.24.




a dry flask, 9 (27 mg; 0.04 mmol) was dissolved in anh. DMF (1 mL),
and 6b (12 mg; 0.04 mmol; 1.5 equiv) was added. The reaction
mixture was stirred under Ar at RT for 18 h. The solvent was
evaporated in vacuo to obtain crude t-butyl SucCa/IdoCa (39 mg)
which was used without further purification. Deprotection was
performed according to general procedure B. Preparative RP-HPLC
conditions: 30% MeCN (+0.1% TFA) in H2O (+0.1% TFA);
isocratic. Yield: 15 mg (41% over two steps) of yellow solid. 1H NMR
(600 MHz, DMSO-d6; for NMR numbering, see Scheme S1): δ 12.59
(br s, 1H, IDO−COOH), 9.88−9.49 (m, 1H, DACH-1), 9.29 (br s,
1H, DACH-1), 8.56 (br s, 1H, DACH-1), 8.32 (br s, 1H, DACH-1),
7.49 (d, J = 7.9 Hz, 1H, IDO-5), 7.36 (d, J = 8.2 Hz, 1H, IDO-8),
7.15−7.10 (m, 1H, IDO-7), 7.07 (s, 1H, IDO-2), 7.01 (t, J = 7.3 Hz,
1H, IDO-6), 6.84−6.60 (m, 1H, SUC-9), 6.60−6.07 (m, 1H, IDO-
14), 4.32−4.12 (m, 1H, IDO-12), 3.73 (s, 3H, IDO-10), 3.32−3.29
(m, 2H, SUC-4), 3.08 (dd, J = 14.6, 5.1 Hz, 1H, IDO-11), 3.03 (dd, J
= 14.6, 7.7 Hz, 1H, IDO-11), 2.95−2.78 (m, 2H, SUC-8), 2.61 (s,
4H, SUC-3), 2.58−2.53 (m, 2H, DACH-2), 2.18−2.08 (m, 2H, 2×
DACH-3), 1.54−1.46 (m, 2H, 2× DACH-2), 1.44−1.25 (m, 6H,
SUC-5, SUC-7, 2× DACH-3), 1.19−1.06 (m, 4H, 2× DACH-4,
SUC-6). 13C NMR (151 MHz, DMSO-d6): δ 177.8 (SUC-2), 173.8
(IDO-13), 164.4 (SUC-10), 163.8 (IDO-15), 163.3 (oxalate), 136.4
(IDO-9), 128.0 (IDO-2), 127.5 (IDO-4), 121.0 (IDO-7), 118.5
(IDO-6), 118.4 (IDO-5), 109.6 (IDO-8), 109.1 (IDO-3), 61.0, 60.9
(2× DACH-2), 55.2 (IDO-12), 40.7 (SUC-8), 37.8 (SUC-4), 32.3
(IDO-10), 30.9 (2× DACH-3), 29.1 (SUC-7), 28.0 (SUC-3), 26.9
(SUC-5), 26.5 (IDO-11), 23.6 (SUC-6), 23.5 (2× DACH-4). MS
(m/z): calcd C31H41N6O12Pt (M − H)−, 884.24; found, 884.40. EA
calcd C31H42N6O12Pt·0.5TFA·0.5H2O: C, 40.38; H, 4.61; N, 8.83.
Found: C, 40.14; H, 4.36; N, 8.69.
(OC-6-34)-[(R)-(1-Carboxy-2-(1-methyl-1H-indol-3-yl)ethyl)-
carbamato][(1R,2R)-1,2-cyclohexanediamino][6-(2,5-dioxopyrroli-
din-1-yl)hexanoato]]oxalatoplatinum(IV) (SucEs/IdoCa). 5b (9 mg,
0.04 mmol, 1.6 equiv) was dissolved in DMF (0.75 mL).
Subsequently, DIPEA (12 μL, 0.07 mmol, 2.5 equiv) and TBTU
(17 mg, 0.04 mmol, 1.7 equiv) were added. After 15 min of stirring at
RT, 9 (20 mg, 0.03 mmol, 1 equiv) was added and stirred further at
RT for 17 h. The solvent was evaporated under reduced pressure, and
the crude product was purified by preparative RP-HPLC [44% MeCN
(+0.1% HCOOH) in H2O (+0.1% HCOOH); isocratic] to obtain t-
butyl SucEs/IdoCa (15 mg, 56%) as a yellow solid. Deprotection was
performed according to general procedure B starting from t-butyl
SucEs/IdoCa (75 mg, 0.08 mmol). Preparative RP-HPLC con-
ditions: 28% MeCN (+0.1% HCOOH) in H2O (+0.1% HCOOH);
isocratic. Yield: 40 mg (55%) of yellow solid. 1H NMR (600 MHz,
DMSO-d6; for NMR numbering, see Scheme S1): δ 12.60 (s, 1H,
IDO−COOH), 9.26 (t, J = 9.3 Hz, 1H, DACH-1), 8.47 (br s, J = 4.9
Hz, 1H, DACH-1), 8.32 (br s, 1H, DACH-1), 8.24 (t, J = 9.6 Hz, 1H,
DACH-1), 7.49 (d, J = 7.9 Hz, 1H, IDO-5), 7.36 (d, J = 8.2 Hz, 1H,
IDO-8), 7.15−7.10 (m, 1H, IDO-7), 7.07 (s, 1H, IDO-2), 7.01 (t, J =
7.4 Hz, 1H, IDO-6), 6.58 (d, J = 7.9 Hz, 1H, IDO-14), 4.32−4.14 (m,
1H, IDO-12), 3.73 (s, 3H, IDO-10), 3.32−3.29 (m, 2H, ido-N-4),
3.08 (dd, J = 14.7, 5.0 Hz, 1H, IDO-11), 3.02 (dd, J = 14.8, 7.8 Hz,
1H, IDO-11), 2.60 (s, 4H, SUC-3), 2.57−2.52 (m, 2H, DACH-2),
2.28−2.18 (m, 2H, SUC-8), 2.16−2.05 (m, 2H, 2× DACH-3), 1.54−
1.46 (m, 2H, 2× DACH-4), 1.46−1.36 (m, 5H, SUC-5, SUC-7, 1×
DACH-3), 1.36−1.26 (m, 1H, 1× DACH-3), 1.20−1.05 (m, 4H, 2×
DACH-4, SUC-6). 13C NMR (151 MHz, DMSO-d6): δ 180.9 (SUC-
10), 177.8 (2× SUC-1), 173.9 (IDO-13), 163.8 (IDO-15), 163.4,
163.4 (2× oxalate), 136.5 (IDO-9), 128.1 (IDO-2), 127.6 (IDO-4),
121.1 (IDO-7), 118.6 (IDO-6), 118.4 (IDO-5), 109.6 (IDO-8), 109.1
(IDO-3), 61.2, 60.9 (2× DACH-2), 55.2 (IDO-12), 37.7 (SUC-4),
35.5 (SUC-8), 32.3 (IDO-10), 31.0, 30.9 (2× DACH-3), 28.0 (SUC-
3), 26.9 (SUC-7), 26.6 (IDO-11), 25.7 (SUC-6), 24.9 (SUC-7), 23.6,
23.5 (2× DACH-4). MS (m/z): calcd C31H41N5O12NaPt (M + Na)+,
893.23; found, 893.22. EA calcd C31H39N5O12Pt·1.5H2O: C, 41.47;




IdoEs). 4 (81 mg, 0.26 mmol, 1.1 equiv) and 5b (54 mg, 0.26 mmol,
1.1 equiv) were dissolved in DMF (5 mL). TEA (97 μL, 0.70 mmol, 3
equiv) and TBTU (186 mg, 0.58 mmol, 2.5 equiv) were added
subsequently. After 15 min of stirring at RT, 9 (100 mg, 0.23 mmol, 1
equiv) was added and stirred further at RT for 17 h. The solvent was
evaporated under reduced pressure, and the crude product was
purified by preparative RP-HPLC [45% MeCN (+0.1% HCOOH) in
H2O (+0.1% HCOOH); isocratic] to obtain Boc-SucEs/IdoEs (37
mg, 34%) as a yellow solid. Deprotection was performed according to
general procedure B starting from Boc-SucEs/IdoEs (35 mg, 0.04
mmol). Preparative RP-HPLC conditions: 25% MeCN (+0.1% TFA)
in H2O (+0.1% TFA); isocratic. Yield: 25 mg (65%) of yellow solid.
1H NMR (600 MHz, DMSO-d6; for NMR numbering, see Scheme
S1): δ 8.53−8.41 (m, 1H, DACH-1), 8.27 (t, J = 9.4 Hz, 1H, DACH-
1), 8.21 (br s, 1H, DACH-1), 8.09−7.94 (m, 3H, IDO-14), 7.67−
7.54 (m, 2H, DACH-1, IDO-5), 7.43 (d, J = 8.3 Hz, 1H, IDO-8),
7.21−7.16 (m, 1H, IDO-7), 7.12 (s, 1H, IDO-2), 7.09−7.04 (m, 1H,
IDO-6), 4.18−4.08 (m, 1H, IDO-12), 3.75 (s, 3H, IDO-10), 3.36−
3.29 (m, 3H, SUC-4, 1× IDO-11), 3.03 (dd, J = 15.3, 8.3 Hz, 1H,
IDO-11), 2.66−2.54 (m, 6H, SUC-3, DACH-2), 2.32−2.22 (m, 2H,
SUC-8), 2.17 (d, J = 10.8 Hz, 1H, DACH-3), 2.11−2.01 (m, 1H,
DACH-3), 1.58−1.50 (m, 2H, 2× DACH-4), 1.50−1.39 (m, 6H,
SUC-5, SUC-7, 2× DACH-3), 1.23−1.12 (m, 3H, SUC-6, 1×
DACH-4), 1.10−1.00 (m, 1H, DACH-4). 13C NMR (151 MHz,
DMSO-d6): δ 180.8 (SUC-10), 177.8 (SUC-2), 174.1 (IDO-13),
163.7, 163.7 (2× oxalate), 158.1, 157.9, 157.7, 157.5 (4× TFA), 136.8
(IDO-9), 129.0 (IDO-2), 127.2 (IDO-4), 121.4 (IDO-7), 118.7
(IDO-6), 118.4 (IDO-5), 109.9 (IDO-8), 106.7 (IDO-3), 61.5, 60.4
(2× DACH-2), 53.2 (IDO-12), 37.6 (SUC-4), 35.4 (SUC-8), 32.4
(IDO-10), 31.0, 30.8 (2× DACH-3), 28.0 (SUC-3), 26.9 (SUC-5),
26.7 (IDO-11), 25.6 (SUC-6), 24.9 (SUC-7), 23.6, 23.5 (2× DACH-
4). MS (m/z): calcd C30H42N5O10Pt (M + H)
+, 827.26; found,
827.23. EA calcd C30H41N5O10Pt·1.5TFA·0.5H2O: C, 39.37; H, 4.35;
N, 6.96. Found: C, 39.37; H, 4.38; N, 7.19.
(OC-6-34)-Acetato[(1R,2R)-1,2-cyclohexanediamine]oxalato[(5-
(2,5-dioxopyrrolidin-1-yl)pentyl)carbamato]platinum(IV) (SucCa/
OAc). In a dry flask, 6b (67 mg, 0.32 mmol, 1.5 equiv) was dissolved
in anh. DMF (3 mL), and 7b (97 mg, 0.21 mmol, 1 equiv) was added.
The reaction mixture was stirred under Ar at RT for 20 h. The solvent
was removed under reduced pressure, and the residue was taken up in
MeOH and precipitated with Et2O. The crude product was purified
via preparative RP-HPLC [15% MeCN (+0.1% HCOOH) in H2O
(+0.1% HCOOH); isocratic] to obtain SucCa/OAc (30 mg; 21%) as
a white solid. 1H NMR (500 MHz, DMSO-d6; for NMR numbering,
see Scheme S1): δ 10.02−9.43 (m, 1H, DACH-1), 8.81−7.95 (m, 3H,
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DACH-1), 6.87−6.21 (m, 1H, SUC-9), 3.31−3.28 (m, 2H, SUC-4),
2.95−2.77 (m, 2H, SUC-8), 2.61 (s, 4H, SUC-3), 2.60−2.53 (m, 2H,
DACH-2), 2.13 (d, J = 8.8 Hz, 2H, DACH-3), 1.95 (s, 3H, acetate),
1.51 (d, J = 8.9 Hz, 2H, DACH-4), 1.47−1.25 (m, 6H, SUC-5, 2×
DACH-3, SUC-7), 1.21−1.04 (m, 4H, 2× DACH-4, SUC-6). 13C
NMR (126 MHz, DMSO-d6): δ 178.4 (acetate−CO), 177.8 (SUC-
2), 164.4 (SUC-10), 163.4, 163.3 (2× oxalate), 61.2, 60.9 (2×
DACH-2), 40.6 (SUC-8), 37.8 (SUC-4), 31.0, 30.8 (2× DACH-3),
29.1 (SUC-7), 28.0 (SUC-3), 26.9 (SUC-5), 23.6 (SUC-6), 23.5
(DACH-4), 22.9 (acetate−CH3). MS (m/z): calcd C20H30N4O10Pt
(M + H)+, 684.18; found, 684.18. EA calcd C20H32N4O10Pt·H2O: C,
34.24; H, 4.88; N, 7.99. Found: C, 34.47; H, 4.80; N, 8.28.
(OC-6-44)-Acetato[(1R,2R)-1,2-cyclohexanediamino][3-(1-meth-
yl-1H-indol-3-yl)propanoato]oxalatoplatinum(IV) (OAc/IPAEs).
IPA (11 mg, 0.06 mmol, 1.1 equiv) was dissolved in DMF (1 mL),
and TEA (10.4 μL, 0.06 mmol, 1.5 equiv) and TBTU (20 mg; 0.06
mmol; 1.3 equiv) were added. After 10 min at RT, 6b (24 mg, 0.05
mmol, 1 equiv) was added and stirred further at RT for 16 h. The
solvent was evaporated under reduced pressure, and the crude
product was purified by preparative RP-HPLC [31% MeCN (+0.1%
HCOOH) in H2O (+0.1% HCOOH) isocratic] to obtain OAc/
IPAEs (7 mg; 20%) as a white solid. 1H NMR (500 MHz, DMSO-d6;
for NMR numbering, see Scheme S1): δ 8.31 (br s, 4H, DACH-1),
7.48 (d, J = 7.9 Hz, 1H, IDO-5), 7.35 (d, J = 8.2 Hz, 1H, IDO-8),
7.12 (t, J = 7.6 Hz, 1H, IDO-7), 7.03 (s, 1H, IDO-2), 7.00 (t, J = 7.4
Hz, 1H, IDO-6), 3.70 (s, 3H, IDO-10), 2.87 (t, J = 7.5 Hz, 2H, IDO-
11), 2.64−2.60 (m, 2H, IDO-12), 2.57−2.53 (m, 1H, DACH-2),
2.44−2.38 (m, 1H, DACH-2), 2.13−2.01 (m, 2H, DACH-3), 1.96 (s,
3H, acetate), 1.49−1.24 (m, 4H, 2× DACH-4, 2× DACH-3), 1.18−
1.07 (m, 1H, DACH-4), 1.03−0.93 (m, 1H, DACH-4); 13C NMR
(126 MHz, DMSO-d6): δ 180.6 (acetate−CO), 178.5 (IDO-13),
163.5 (oxalate), 136.6 (IDO-9), 127.2 (IDO-4), 126.6 (IDO-2),
121.1 (IDO-7), 118.4 (IDO-5), 118.3 (IDO-6), 112.8 (IDO-3), 109.5
(IDO-8), 61.2, 61.0 (2× DACH-2), 36.4 (IDO-12), 32.2 (IDO-10),
30.9, 30.8 (2× DACH-3), 23.5, 23.4 (2× DACH-4), 23.0 (acetate−
CH3), 20.9 (IDO-11). MS (m/z): calcd C22H28N3O8Pt (M − H)−,
657.15; found, 657.16.
UHPLC-Reduction Experiments. The platinum(IV)−succini-
mide complexes were dissolved in 2% DMF in phosphate buffer (500
mM, pH 7.4) to a final concentration of 2 mM. The solutions were
then mixed 1:1 with a 20 mM stock of L-ascorbic acid in phosphate
buffer (500 mM, pH 7.4) to obtain final concentrations of 1 mM
complex, 10 mM L-ascorbic acid, and 1% DMF. The samples were
incubated at 20 °C and measured on a Dionex UltiMate 3000 RS
UPLC system with a Waters Acquity UPLC BEH C18 column (3 ×
50 mm, pore size 1.7 μm) and absorption detection at 220 nm. Data
points were taken at t = 0 and every 30 min for 6 h.
SEC−ICP−MS Studies. FCS was purchased from Sigma-Aldrich
and buffered with 150 mM phosphate buffer (pH 7.4) to guarantee a
stable pH. The maleimide-bearing platinum(IV) complexes were
dissolved in 10% DMF in 150 mM phosphate buffer (pH 7.4) to 1
mM and diluted 1:10 in serum to obtain a final concentration of 100
μM. The samples were then incubated in the autosampler at 37 °C for
24 h and analyzed every 1 h. Between each sample, a pure water blank
was measured. For SEC−ICP−MS measurements, an Agilent 1260
Infinity system coupled to an Agilent 7800 ICP−MS equipped with a
dynamic reaction cell was used. Oxygen (purity 5.5, Messer Austria
GmbH, Gumpoldskirchen, Austria) was used as reaction gas. HPLC
parameters are given in Table S4, and ICP−MS operation parameters
are given in Table S5.
Cell Culture. The human SKOV3 (ATCC HTB-77, ovarian
adenocarcinoma) and HCT116 (ATCC CCL-247, colorectal
carcinoma) cells were maintained in McCoy’s 5A (Sigma-Aldrich,
MO, USA). Murine CT26 (ATCC CRL-2638, colon carcinoma) and
murine GL261 (glioblastoma, kindly provided by T. Felzmann,
Vienna, Austria) were kept in Dulbecco’s modified Eagle’s medium
(DMEM)/F12 (1:1). Human OVCAR (ATCC HTB-161, ovarian
adenocarcinoma), murine AB12 (mesothelioma), murine AE17
(mesothelioma), and the human melanoma (VM1, VM7, and
VM15, established at our institute47) cancer cell lines were
maintained in RPMI-1640. ID8 (ovarian adenocarcinoma, kindly
provided by F. Roby, Kansas, USA) was kept in DMEM
(supplemented with 5 μg/mL insulin, 5 μg/mL transferrin, and 5
ng/mL Na2SeO3), and murine K7M2 (ATCC CRL-2836, osteosar-
coma) was kept in DMEM medium. All media were supplemented
with 10% FBS (PAA, Linz, Austria) in a humidified atmosphere at 37
°C and 5% CO2.
Cytotoxicity Assay. The cells were seeded at 3500−6000 cells/
well in 96-well plates depending on the proliferation rate of the
respective cell line and allowed to recover for 24 h. Subsequently, the
cells were treated at indicated concentrations for 48 or 72 h. Cells
were additionally incubated with 5-fold equimolar concentrations of
ascorbic acid to increase the reduction rate of the compounds. Cell
viability was measured by the MTT-based vitality assay (EZ4U;
Biomedica, Vienna, Austria), following the manufacturer’s recom-
mendations. Full dose−response curves were generated using
GraphPad Prism software to calculate IC50 values (drug concen-
trations at 50% reduced cell viability compared to control).
pH2AX Signal Detection and Quantification. HCT116 cells
were seeded on polytetrafluoroethylene-printed spot slides (E63424-
06, Science Services GmbH, Munich, Germany) at a density of 4000
cells/spot. On the next day, cells were exposed to the compounds for
24 h, at 50 μM and fixed in a 4% formaldehyde solution in phosphate-
buffered saline (PBS) with a pH adjusted to 7.4 (158127, Merck,
Darmstadt, Germany) for 15 min at RT. Spots were washed thrice
with PBS each for 5 min, and samples were then incubated in a
blocking buffer [PBS, 5% albumin (Carl Roth, Karlsruhe, Germany),
0.3% Triton X-100 (T8787, Merck, Darmstadt, Germany)] for 1 h at
RT. Next, samples were incubated with a primary antibody solution of
phospho-histone H2A.X (Ser139) (clone 20E3, #9718, Cell Signaling,
Danvers, USA) at a dilution of 1:200 in an antibody dilution buffer
[PBS with 1% albumin (Carl Roth, Karlsruhe, Germany) and 0.3%
Triton X-100 (T8787, Merck, Darmstadt, Germany)] for 1 h at RT.
Subsequently, samples were washed twice with PBS (5 min each),
incubated with goat anti-rabbit antibody linked to Alexa Fluor 488 (A-
11008, Thermo Fisher Scientific, Massachusetts, USA), and diluted
1:500 in antibody dilution buffer for 1 h at RT. Next, samples were
incubated with rhodamine-labeled wheat germ agglutinin (RL-1022,
Vector Laboratories, California, USA) at a concentration for 5 μg/mL
for 15 min at RT, and spots were washed twice in PBS, embedded in
vectashield mounting medium with DAPI (VECH-1200, Szabo-
Scandic, Vienna, Austria), and analyzed using a LSM700 confocal
microscope (Zeiss Axio Observer.Z1, inverse, 63× plan-apochromat
NA 1.4 Oil DIC objective). Per condition, five representative images
were taken (16-bit, 101.61 × 101.61 μm). Images were analyzed using
ImageJ software. Nuclear area was selected by applying default
threshold to the DAPI channel of each image. Then, Alexa Fluor 488
signal (integrated density) was measured and normalized to nuclear
area.
Cell Cycle Analysis. The cells were seeded at 600,000 cells/well
in six-well plates and allowed to recover for 24 h. On the next day,
cells were exposed to the compounds for 24 h, then trypsinized, and
collected. Subsequently, cells were washed with PBS and centrifuged
(400g, 5 min), and the cell pellet was resuspended in 100 μL of 0.9%
NaCl solution. The cell suspension was then added dropwise to 1.8
mL of ice-cold 80% ethanol and incubated for 48 h at −20 °C. The
fixated cells were centrifuged (6200g, 2 min), and the cell pellet was
diluted in 0.5 mL of PBS with 0.1 mg/mL RNAse A (R5503, Merck,
Darmstadt, Germany), which was previously heat-activated (10 min at
96 °C), and samples were incubated for 30 min at 37 °C to remove
RNA content. Next, to stain DNA, propidium iodide (81845, Merck,
Darmstadt, Germany) at a concentration of 5 μg/mL was added,
samples were incubated for 30 min on ice and subsequently measured
by flow cytometry.
ICP−MS Measurements of HCT116 Cells and Tumor
Tissues. HCT116 cells were seeded at 6 × 105 cells/well in a six-
well plate and allowed to settle for 24 h. Cells were exposed to drugs
at 20 μM for 3 h under normal cell culture conditions. Cells were
washed twice with PBS and lysed at RT in 500 μL HNO3 (≥69%,
Rotipuran Supra, Carl Roth, Karlsruhe, Germany) for 1 h. 400 μL of
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the lysate was transferred to 7.6 mL of ultrapure water (18.2 MΩ cm,
Milli-Q Advantage, Darmstadt, Germany).
For tissue digestion, approx. 25−50 mg of tissue was weighed into
perfluoralkoxy tubes, and 2 mL of HNO3 and 100 μL H2O2 (30%,
Suprapur, Merck, Darmstadt, Germany) were added. The solutions
were placed on a hot plate and heated up for 7 h using a temperature
program with a maximum of 200 °C. The liquids were transferred to
15 mL tubes with the remaining solution being removed by washing
twice with 4 mL of ultrapure water.
Platinum concentrations were measured using an Agilent 7800
ICP-QMS instrument (Agilent Technologies, Tokyo, Japan)
equipped with an Agilent SPS 4 autosampler (Agilent Technologies,
Tokyo, Japan) and a MicroMist nebulizer at a sample uptake rate of
approx. 0.2 mL/min. The Agilent MassHunter software package
(Workstation Software, Version C.01.04, 2018) was used for data
evaluation. All of the measured samples were blank corrected (for the
cell culture data, wells containing no cells were used). The
instrumental parameters for the ICP−MS are summarized in Table
S6. Elemental standard solutions were purchased from Labkings
(Hilversum, The Netherlands). The instrument was tuned on a daily
basis.
log D7.4 Determination by ICP−MS. 50 mM stock solutions of
the succinimide complexes in DMF were diluted in phosphate buffer
(20 mM, pH 7.4, pre-saturated with n-octanol) to a final
concentration of 50 μM drug and 0.1% DMF. The platinum content
of these aqueous solutions was measured by ICP−MS (see above).
The solutions were mixed 1:1 with n-octanol and shaken on a 360°
rotatable rack for 3 h. The solutions were centrifuged for 5 min (860g,
RT), the aqueous layers were carefully removed, and their Pt content
was measured by ICP−MS. Experiments were performed and
measured in duplicates, and averages were used for further









RNA Isolation and Detection of IDO Levels by Real-Time
PCR. Total RNA was isolated from cells using the TRIzol reagent
(15596-026, Thermo Fisher Scientific, Massachusetts, USA),
according to the manufacturer’s instructions. RNA was reverse
transcribed to complementary DNA (cDNA) using RevertAid
Reverse Transcriptase (EP0441, Thermo Fisher Scientific, Massachu-
setts, USA). The real-time PCR method is described elsewhere.58 In
short, cDNA samples were diluted 1:25 and analyzed using Maxima
SYBR Green/ROX qPCR Master Mix (2×) (K0221, Thermo Fisher
Scientific, Massachusetts, USA) in a CFX96 Touch real-time PCR
detection system (Bio-Rad Laboratories, California, USA) for their
specific mRNA content using the following primer sequences
purchased from Eurofins Genomics: human β-actin: fwd (5′-GGA
TGC AGA AGG AGA TCA CTG-3′), rev (5′-CGA TCC ACA CGG
AGT ACT TG-3′); human IDO: fwd (5′-GTC ATG GAG ATG
TCC GTA AG-3′), rev (5′-CTT GGA GAG TTG GCA GTA AG-
3′); murine β-actin: fwd (5′-ATG GAG GGG AAT ACA GCC-3′),
rev (5′-TTC TTT GCA GCT CCT TCG TT-3′); murine IDO
transcript 1: fwd (5′-ATG TTG GCT TTG CTC TAC CA-3′), rev
(5′-GAC CAC CTC AGG GTT TAG CG-3′).
Long-Term Cytotoxicity Assay. SKOV3 cells were seeded in
duplicates at 5000 cells/well in 24-well plates and allowed to recover
for 24 h. Subsequently, the cells were treated at the indicated
concentrations for 168 h. Cells were fixed with ice-cold methanol (20
min at 4 °C), washed with PBS, and stained with crystal violet.
Subsequently, colony formation was inspected, and the fluorescence
signal was detected using Typhoon Trio imager (GE Healthcare,
Little Chalfont, UK) at 610/30 nm BP and analyzed by ImageJ
software. Fluorescence values of empty wells were subtracted from
each value, and full dose−response curves were generated to calculate
IC50 values (drug concentrations at 50% reduced fluorescence
intensity compared to control).
Reduction and 1-MDT Release in SKOV3 Lysates. SKOV3
cells were grown in four T225 mm2 cell culture flasks to reach a high
cell number. On the day of cell lysate isolation, cells were washed with
PBS, scraped from the surface, and centrifuged. Each cell pellet was
lysed in ∼160 μL lysis buffer (15 mM NaCl 0.5% Triton X, ultrapure)
and incubated on ice for 1 h. The samples were then centrifuged for
15 min at 14,000 rpm (4 °C), and the cleared lysate was pooled and
kept at −80 °C until analysis. Cell lysates were treated with 2 mM
stock solutions of respective complexes in 4% DMF and phosphate
buffer (100 mM, pH 7.4) to obtain a final compound concentration of
100 μM and incubated at 37 °C. After 0, 4, 24, and 72 h, three volume
equivalents of cold MeOH were added to sample aliquots. Samples
were stored at 4 °C for 10 min and centrifuged (15,080g, 4 °C, 10
min). LC−MS analysis of the supernatant was performed on an
Agilent 1260 Infinity system using a Waters Atlantis T3 column (150
mm × 4.6 mm) and absorption detection at 230 nm, coupled to a
Bruker amaZon SL ESI-IT mass spectrometer. Milli-Q water,
containing 0.1% formic acid, and acetonitrile, containing 0.1% formic
acid, were used as eluents. A gradient of 1−99% acetonitrile in 20 min
was used.
Colorimetric Kyn Assay. SKOV3 cells were seeded at 5000 cells/
well in 96-well plates and allowed to recover for 24 h. Cells were
treated for 72 h. Supernatants (200 μL/well) and blank medium were
transferred to microcentrifuge tubes, and cell viability was measured
by MTT assay. To precipitate proteins, the supernatants were mixed
with 100 μL 30% (w/v) trichloroacetic acid. N-Formyl-Kyn was
hydrolyzed to Kyn by incubating the supernatants for 30 min in a
thermoblock at 50 °C and 300 rpm. The supernatants were cleared by
centrifugation (10 min at 10,000g), and 100 μL of the clear
supernatants was transferred to a fresh 96-well plate in duplicates and
incubated with 100 μL Ehrlich’s reagent [2% 4-(dimethylamino)-
benzaldehyde (Sigma-Aldrich, D2004, MO, USA) in acetic acid
(Merck, Darmstadt, Germany)] for 10 min at RT. For the washout
experiments, cells were seeded in quintuplicates. 72 h after treatment,
the cell supernatant was exchanged with serum-free medium. After 24
h incubation, the supernatant was analyzed, as described above. The
absorption of Kyn was measured at 490 nm (reference 620 nm), and
the absorbance of blank medium was subtracted. The Kyn
concentrations were calculated using a standard curve [generated
from L-Kyn (Sigma-Aldrich, K8625, MO, USA) dilution series in
blank medium] and normalized to cell viability.
Animals. 8−12 week old Balb/c and SCID mice (Harlan
Laboratories, San Pietro Al Natisone, Italy) were kept in a
pathogen-free environment. Every procedure was carried out under
sterile conditions and according to the regulations of the Ethics
Committee for the Care and Use of Laboratory Animals at the
Medical University Vienna.
Organ Distribution in SKOV3-Bearing SCID Mice. SKOV3
cells (1.5 × 106 cells in 50 μL serum-free medium) were injected
subcutaneously into the right flank of male SCID mice. When the
tumors reached a volume of at least ∼340 mm3, the mice (n = 2 per
group) were treated once with the compounds iv at concentrations
equimolar to 9 mg/kg oxaliplatin (MalEs/IdoCa 19.7 mg/kg,
MalCa/IdoCa 20.5 mg/kg, MalEs/IdoEs 21.4 mg/kg, and MalCa/
IdoEs 21.5 mg/kg) in 20% propylene glycol (PG). OAc/OAc (12.1
mg/kg) was applied in 0.9% NaCl and oxaliplatin (9.0 mg/kg) in 5%
glucose. After 24 h, the animals were anesthetized and blood drawn by
heart puncture. Then, the animals were sacrificed by cervical
dislocation, and tumors and organs were collected for the measure-
ment with ICP−MS. For plasma isolation, blood was collected in
ethylenediaminetetraacetic acid (EDTA)-coated tubes and centri-
fuged for 10 min at 900g at 4 °C. Plasma was transferred to a new
tube and centrifuged once more to remove residual red blood cells.
Detection of Trp and Its Metabolites in Cell Culture and in
Tumor Tissue by LC−HRMS. Sample Preparation. The cell
supernatant was analyzed using adapted protocols from Simoń-Manso
et al.59 SKOV3 cells were seeded at 5000 cells/well in a 96-well plate.
24 h after seeding, cells were treated for 72 h. The medium was
exchanged to serum-free medium, and cells were incubated for 24 h.
To 50 μL of cell supernatant or blank medium, 50 μL of fully 13C
internal standard (labeled yeast extract prepared in 2 mL of H2O;
ISOtopic solutions e.U., Vienna, Austria) and 400 μL of MeOH
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(LC−MS grade, Sigma-Aldrich, Vienna, Austria) were added for
protein precipitation (−20 °C overnight) and centrifugation (14,000g,
4 °C, 15 min). 100 μL of aliquots was dried for direct LC−HRMS
analysis.
To 50 mg of tumor tissue, 50 μL of fully 13C internal standard
(labeled yeast extract prepared in 2 mL of H2O; ISOtopic solutions
e.U., Vienna, Austria) and 950 μL of 80% MeOH (LC−MS grade,
Sigma-Aldrich, Vienna, Austria) were added and homogenized in a
Dounce-type glass tissue grinder. The homogenate was collected, the
tissue homogenizer was washed twice with 400 μL 80% MeOH (LC−
MS grade, Sigma-Aldrich, Vienna, Austria), and the washing solution
was added to the homogenate. The samples were vortexed,
centrifuged (14,000g, 4 °C, 20 min), and kept on dry ice until
further processing. 500 μL of tumor sample aliquots was dried for
direct LC−HRMS analysis.
LC−HRMS Analysis. All samples were resuspended in 100 μL of
water (supernatant sample: same volume; tumor samples 5-fold
concentration) and measured using a 12 min method based on
reversed-phase chromatography (column: HSS T3, 1.8 μm, 2.1 × 150
mm, Waters) and high-resolution mass spectrometry (Orbitrap HF,
Thermo). For quantification, multi-point calibration with external
standard mixes (Kyn, Trp, and kynurenic acid) using co-eluting 13C
internal standards was performed and analyzed by Skyline 20.2.0.286.
For 1-MDT, relative quantification based on 13C Trp normalization
was performed.
Anticancer Activity Experiment. CT26 cells (5 × 105 cells in 50
μL of serum-free medium) were injected subcutaneously into the
right flank of Balb/c mice. On day 3, when the tumors were palpable,
the mice (n = 4 per group) were treated with the compounds iv at
concentrations equimolar to 9 mg/kg oxaliplatin (MalEs/IdoEs 23
mg/kg in 10% PG, MalCa/IdoEs 22.2 mg/kg in 15% PG, MalCa/
IdoCa 20.6 mg/kg in 15% PG, and MalEs/IdoCa 21 mg/kg in 15%
PG/PBS) twice a week (Mon/Thu or Tue/Fri) for 2 weeks. Every
day, the animals were monitored for body weight and the enhanced
stress level, and the tumor size was measured using a caliper according
to the formula length × width2/2.
Sample Preparation of Murine Tissue for Flow Cytometry.
CT26 cells (5 × 105 cells in 50 μL of serum-free RPMI medium) were
injected into the right flank of female Balb/c mice (n = 4 per group).
On day 7, when the tumors reached a mean tumor volume of ∼170
mm3, mice were treated once iv withMalEs/IdoCa at a concentration
equimolar to 9 mg/kg (dissolved in 20% PG in PBS) or solvent only.
After 24 h, the animals were sacrificed, and tumor tissues and the
tumor-draining lymph nodes were isolated. Tissues were collected in a
tube with 750 μL of ice-cold PBS containing 5% FBS and cut into
small pieces. Samples were digested using PBS containing 50 mg/mL
collagenase (C2139, Merck, Darmstadt, Germany) and 50 mg/mL
DNase I (DN25, Darmstadt, Germany) and filtered several times
through a 70 μm cell strainer (734-2761, VWR, Pennsylvania, USA).
The samples were centrifuged, and cell pellets were treated with
ammonium−chloride−potassium (ACK)-buffer (150 mM NH4Cl, 10
mM KHCO3, 127 μM EDTA, pH 7.2−7.4) to lyse red blood cells and
centrifuged in a Würzburg buffer (PBS containing 5% FBS, 5 mM
EDTA, 20 μg/mL DNase I).
Human PBMC Isolation. Blood was drawn from healthy donors
and collected in EDTA-coated tubes. Blood was diluted in PBS−2
mM EDTA (Titriplex III, Merck, Darmstadt, Germany) 1:2 and
carefully layered on top of Ficoll-Paque solution (Merck, Darmstadt,
Germany) in a 50 mL falcon tube. Subsequently, blood was
centrifuged for 40 min, at 400g, at 20 °C without active deceleration
to obtain a buffy coat layer containing PBMC. Upper layer, containing
serum, was aspirated, and the buffy coat layer was collected and
washed in PBS containing 2 mM EDTA. PBMCs were diluted in
RPMI-1640 supplemented with 10% FBS. For later analysis, PBMCs
were frozen in RPMI-1640−40% FBS−15% DMSO and stored in
liquid nitrogen.
Immune Co-culture and Sample Preparation for Flow
Cytometry. PBMCs were thawed and slowly dropped into warm
medium at a rate of 1 drop/5 s. PBMCs were then centrifuged (10
min, 400g) and washed with warm AIM V medium (12055091,
Thermo Fisher Scientific, Massachusetts, USA). PBMCs were co-
cultured with SKOV3 at a ratio of 2:1 (PBMC/SKOV3) in 12-well
CytoOne plates (CC7682-7512, Starlab, Hamburg, Germany). In the
presence of IL-2 (SRP3085, Merck, Darmstadt, Germany) at a
concentration of 80 ng per 106, PBMCs were added. To induce Treg
differentiation, OKT3 monoclonal CD3 antibody (317302, BioL-
egend, California, USA) and TGF-β1 CHO (AF-100-21C-10 μg,
Eubio, Vienna, Austria) were added at concentrations of 4 μg and 10
ng per 106 PBMC, respectively. Cells were incubated with drugs at
nontoxic concentrations of 10 μM for oxaliplatin and 50 μM for
prodrugs. After 3 days, 250 μL of fresh AIM V medium was added,
and cells were incubated for another two days. On the day of
measurement, supernatant, containing PBMC, was collected.
Flow Cytometry. Cells were washed with PBS and stained using
the Aqua Zombie Fixable Viability Kit (423101, BioLegend,
California, USA), according to the manufacturer’s instructions. Cells
were then stained with fluorescent dye-labeled antibodies, according
to the manufacturer’s instructions (Table S7). For nuclear FOXP3
staining, cells were fixated using a True-Nuclear Transcription Factor
Buffer Set (424401, BioLegend, California, USA), in accordance with
manufacturer’s instructions. Single stains for each antibody using the
AbC Total Antibody Compensation Bead Kit (A10497, Thermo
Fisher) were performed to generate compensation matrices. Sample
acquisition was performed using an LSRFortessa X-20 cell analyzer
(BD Biosciences, New Jersey, USA). Data analysis was performed
using FlowJo software (FlowJo LLC, Oregon, USA) after processing
with the flowAI plugin to remove unwanted events resulting from
changes in the flow rate.60 The cleaned up data were analyzed using
the gating strategy, as shown in Figure S15 for murine tissue and
Figure S16 for human co-culture experiment.
Statistical Analysis. All data are presented as mean ± SD.
Comparison between groups was analyzed by unpaired two-tailed
Student’s t-test or multi comparison (ANOVA) with Dunnett’s or
Bonferroni post-hoc-test. Statistical analysis was performed using
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Figure S2: SEC-ICP-MS traces of complexes (A) SucEs/IdoCa, (B) SucCa/IdoCa, (C) SucCa/IdoEs and (D) 
SucEs/IdoEs after incubation in fetal calf serum (+150 mM phosphate buffer, pH 7.4) at 37°C. No 














Figure S3: Reduction kinetics of reference compounds with AA at 20°C, measured by UHPLC and UV 
absorption at 220 nm. A: Comparison of OAc/IPAEs with amino-group containing SucCa/IdoEs; B: 
Reductive stability of reference compounds with no 1MDT-like ligand. AUC-values were normalized to 




Figure S4: Reduction kinetics of OAc/IPAEs and SucCa/IdoEs in the presence of dithiothreitol (DTT) at 
20°C, measured by UHPLC. The complex OAc/IPAEs does not have a free amino group on its 1-MDT-like 
ligand and is stable under these conditions, whereas SucCa/IdoEs is readily reduced. Experimental 
conditions: 1 mM complex, 10 mM DTT in 1% DMF and 500 mM phosphate buffer (pH 7.4). 













































































Figure S5: Cytotoxicity determination. HCT116 or CT26 cancer cells were treated for 72 h with increasing 
drug concentrations in the presence or absence of 5-fold equimolar amount of AA. The viability of the 
cells was analyzed by MTT assay. Data shown are mean +/- standard deviation of triplicates from one 
exemplary experiment. Significance was calculated using multiple comparisons (two-way ANOVA) * 





Figure S6: DNA damage levels. HCT116 cells were treated with the respective drugs at 50 µM for 24 h in 
the absence or presence of 5-fold excess AA. (A) Cells were fixed and stained with TRITC-phalloidin 
(magenta), DAPI (white) and pH2AX antibody (green). Shown are representative fluorescence images 
(scale bar 20 µm). (B) pH2AX fluorescence intensity signals were quantified and are depicted as 
mean ± SD from five images. Significance compared to control (ctrl) was calculated by mixed-effects 
analysis and Sidak’s multiple comparisons test. Significance comparing conditions with and without AA 





Figure S7: Cell cycle analysis. HCT116 cells were treated with the respective drugs at 50 µM (10 µM in 
case of oxaliplatin) for 24 h in the absence or presence of 5-fold excess AA. Cells were analyzed through 
flow cytometry and cell cycle phases were allocated according to the DNA content. (A) Exemplary 
histogram of cell cycle distribution. (B) Graph shows percentage of cell cycle distribution. Bars depict 
mean ± SD from two independent experiments. Statistical significance compared to respective control 
was calculated by 2way ANOVA and Tukey’s multiple comparisons test. * p < 0.05, *** p < 0.001, **** p 





Figure S8: mRNA levels of IDO transcript in (A) human cell lines or (B) murine cell lines normalized to the 




Figure S9: Proliferation rate of different cancer cell models: 250 000 cells were seeded and counted every 





Figure S10: (A) Colorimetric measurement of Kyn in cell supernatants from SKOV3 cells after 72 h 
treatment at sub-toxic concentrations (2 mM). Values were normalized to cell amount based on their 
metabolic capacity (B) LC-HRMS measurement of the supernatants from (A) to detect Kyn levels. Values 
were normalized to cell amount based on their metabolic capacity. Data is presented as mean +/- SD 
from 5 replicates. Significance was calculated by multiple comparison analysis (one-way ANOVA) and 




Figure S11: Inhibition of kynurenine pathway in tumor tissue. (A) Scheme shows downstream catabolites 
of IDO activity. (B) Relative quantification by LC-HRMS of 1-MDT levels from tumor tissue. (C) Ratio of 
tryptophan to kynurenine level in tumor tissue. Significance of the quantified metabolites by LC-HRMS 
was calculated by ordinary one-way ANOVA and Tukey’s multiple comparisons test. ** p<0.01, *** 






Figure S12: (A) Therapy of CT26-bearing Balb/c mice treated (i.v.) with MalCa/IdoCa or MalCa/IdoEs at 
concentrations equimolar to 9 mg/kg oxaliplatin. Tumor growth was measured daily. Each graph shows 
individual values from one treatment group. (B) Kaplan-Meier blot from (A). Significance was calculated 





Figure S13: Therapy of CT26 bearing Balb/c mice treated (i.v.) with MalEs/IdoEs (A) or MalEs/IdoCa (B) 
at concentrations equimolar to 9 mg/kg oxaliplatin. Tumor growth was measured daily. Left graph shows 
mean ± SEM, black arrows indicate treatments. Significance was calculated in comparison to the solvent 
group and within each group by multiple comparison analysis and 2-way ANOVA, respectively. * p<0.05, 
** p<0.01, *** p<0.001, **** p<0.0001. Middle and right graphs show individual values from each one 
treatment group. (C) and (D) show respective Kaplan-Meier blot from (A) and (B). Significance was 





Figure S14: Therapy of CT26-bearing Balb/c mice treated (i.v.) with oxaliplatin or MalCa/IdoCa at 
concentrations equimolar to 9 mg/kg oxaliplatin. (A) Tumor growth was measured daily and is shown as 
mean ± SEM. Black arrows indicate treatments. Significance was calculated in comparison to the solvent 
group and within each group by multiple comparison analysis and 2-way ANOVA, respectively. 
Significance between curves was calculated using paired t test. * p<0.05, ** p<0.01, *** p<0.001, **** 
p<0.0001. (B) shows individual values from (A) from each treatment group. (C) Kaplan-Meier-curve 
showing survival of the mice. Significance was calculated using Log-rank (Mantel-Cox) test compared to 






Figure S15: Gating strategy of CD8+ T cells, CD4+ T cells and FoxP3+ CD4+ Treg from the mouse experiment 





Figure S16: Gating strategy of human FoxP3+ CD4+ Treg from the human PBMC – SKOV3 tumor cell co-
culture experiment. 





Figure S17: 1H- and 13C-NMR spectra of MalCa/IdoEs in DMSO-d6. The 1H-peaks at ~9.7, ~8.7 and 






Figure S18: 1H- and 13C-NMR spectra of MalCa/IdoCa in DMSO-d6. The 1H-peaks at ~9.7, ~8.3  and in the 
range between 6.1 and 6.8 ppm are split due to the different orientations of the carbamate moieties at 












Figure S20: 1H- and 13C-NMR spectra of MalEs/IdoCa in DMSO-d6. The 1H-peak at ~6.4 ppm is split due to 






Figure S21: 1H- and 13C-NMR spectra of SucEs/IdoCa in DMSO-d6. The 1H-peak at ~6.4 ppm is split due to 













Figure S23: 1H- and 13C-NMR spectra of SucCa/IdoEs in DMSO-d6. The 1H-peaks at ~9.7, ~8.7 and 






Figure S24: 1H- and 13C-NMR spectra of SucCa/IdoCa in DMSO-d6. The 1H-peaks at ~9.7 and in the range 






Figure S25: UHPLC-chromatogram of MalEs/IdoEs at 254 nm. 
 
Figure S26: UHPLC-chromatogram of MalCa/IdoCa at 254 nm. 
 




Figure S28: UHPLC-chromatogram of MalEs/IdoCa at 254 nm. 
 
 
Figure S29: UHPLC-chromatogram of SucEs/IdoEs at 254 nm. 
 




Figure S31: UHPLC-chromatogram of SucCa/IdoCa at 254 nm. 
 





Table S1: Cytotoxicity determined by MTT assay in murine CT26 and human HCT116 colon cancer cells 
after 72 h incubation with and without 5 eq. AA. 
CT26 - IC50 values (µM) - 72 h 
    -      + 5 eq. AA  
  mean   SD   mean   SD ratio 
oxaliplatin 1.90 ± 0.34 
 
2.11 ± 0.69 0.90 
OAc/OAc 42.34 ± 10.99  
33.54 ± 2.85 1.26 
SucCa/OAc 55.17 ± 12.64 
 
40.39 ± 5.62 1.37 
SucEs/IdoCa 90.46 ± 3.14 
 
46.03 ± 3.86 1.97 
SucCa/IdoCa 82.49 ± 8.19 
 
43.65 ± 6.11 1.89 
SucEs/IdoEs 44.94 ± 4.81 
 
18.13 ± 3.48 2.48 
SucCa/IdoEs 31.86 ± 6.11   16.94 ± 3.21 1.88 
         
         HCT116 - IC50 values (µM) - 72 h 
    -      + 5 eq. AA  
  mean   SD   mean   SD ratio 
oxaliplatin 0.76 ± 0.16 
 
0.74 ± 0.14 1.02 
OAc/OAc 14.33 ± 2.50  
11.50 ± 0.92 1.25 
SucCa/OAc 42.02 ± 7.39 
 
21.79 ± 2.38 1.93 
SucEs/IdoCa 82.11 ± 10.02 
 
20.82 ± 2.03 3.94 
SucCa/IdoCa >100 
 
24.74 ± 2.49 ≥4 
SucEs/IdoEs 5.45 ± 1.42 
 
4.89 ± 1.10 1.12 





Table S2: Cytotoxicity determined by MTT assay in human embryonic kidney cells (HEK) and human 












Table S3: Cytotoxicity determined by MTT assay in human SKOV3 and VM7 cancer cells after 72 h 
incubation with and without 5 eq. AA. 
SKOV3 - IC50 values (µM) - 72 h 
     -      + 5 eq. AA  
  mean   SD   mean   SD ratio 
oxaliplatin 0.76 ± 0.16 
 
43.35 ± 4.88 1.05 
OAc/OAc 14.33 ± 2.50    
  
SucCa/OAc >100   
 
>100    
SucEs/IdoCa >100   
 
>100    
SucCa/IdoCa >100    >100    
SucEs/IdoEs >100   
 
>100    
SucCa/IdoEs >100     >100    
 
VM7- IC50 values (µM) - 72 h  
  mean   SD   
oxaliplatin 3.94 ± 0.78 
 
OAc/OAc 43.49 ± 3.33  
SucCa/OAc >100   
 
SucEs/IdoCa >100   
 
SucCa/IdoCa >100    
SucEs/IdoEs >100   
 
SucCa/IdoEs >100     
 
IC50 values (µM) - 72 h 
  HEK293   WRL68   
  mean   SD   mean   SD   
oxaliplatin 2.10 ± 0.27 
 
8.35 ± 1.23 
 OAc/OAc 12.21 ± 0.48 
 
33.58 ± 8.39 
 SucCa/OAc 50.83 ± 10.26 
 
>100 
 SucEs/IdoCa 77.49 ± 16.10 
 
>100 
 SucCa/IdoCa 81.23 ± 21.34 
 
>100 
 SucEs/IdoEs 44.16 ± 8.32 
 
81.69 ± 0.40 
 SucCa/IdoEs 33.19 ± 9.03   76.36 ± 6.67   
S30 
 
Table S4: Ratio of mean platinum level of tissue samples from figure 8. 
Platinum ratio 
    tumor:liver tumor:kidney 




MalEs/IdoCa 0.7 1.2 
MalCa/IdoCa 0.5 0.5 
MalEs/IdoEs 0.2 0.5 



























HPLC column: Acquity UPLC BEH 200Å 1.7 µm, 4.6x150 mm 
Eluent: 50 mM CH3COONH4, pH = 6.8 
Flow rate: 400 μL/min 
Injection volume: 5 μL 
Column temperature: 37°C 
Autosampler temperature: 37°C 
Nebulizer: Quartz 
Spray chamber: Scott type 
Nebulizer gas flow: 1.08 L/min 
Aux. gas flow: 0.9 L/min 
Plasma gas flow: 15 L/min 
Reaction gas (oxygen): 30 % 
ICP RF power: 1550 W 




Table 7: ICP-MS parameters for the 
measurement of platinum levels in 




RF power 1550 W 
Nebulizer MicroMist 
Spray chamber Scott double-pass 
Spraying chamber temp. 2°C 
Monitored Isotopes 185Re, 195Pt, 196Pt 
Measurement modes standard mode  
Plasma gas 15 L min-1 
Nebulizer gas 1.08 L min-1 
Auxiliary gas 0.90 L min-1 
Cones Ni 
Cell entrance –60 V 
Cell exit –110 V 
Integration time 0.1  or 0.3 s 
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Table S8: List of antibodies from Biolegend that were used for multi-color flow cytometry experiments. 





































AF® 647   FOXP3   Mouse   MF-14   1:50 
APC/Cyanine 7  CD45  Human  2D1  1:50 
FITC  CD3  Human  UCHT1  1:33 
PE/Cyanine 7  CD8  Human  SK1  1:66 
APC  CD4  Human  A161A1  1:100 








Scheme S1: NMR numbering scheme for the different ligand systems. 
 
